1
|
Thivel D, Ennequin G, Lambert C, Siroux J, Ratel S, Boscaro A, Pelissier L, Julian V, Cardenoux C, Duclos M, Lazzer S, Pereira B, Boirie Y, Isacco L. Improved walking energy efficiency might persist in presence of simulated full weight regain after multidisciplinary weight loss in adolescents with obesity: the POWELL study. Int J Obes (Lond) 2024; 48:384-393. [PMID: 38052874 DOI: 10.1038/s41366-023-01427-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 11/03/2023] [Accepted: 11/23/2023] [Indexed: 12/07/2023]
Abstract
AIM Weight loss leads to a reduction of the energy cost of walking but the respective implications of the metabolic and mechanic changes remain unknown. The present study compares the post-weight loss energy cost of walking (Cw) with and without a total reload of the induced weight reduction in adolescents with obesity. METHODS Energy cost of walking and substrate use were evaluated during a graded walking exercise (4×6-min at 0.75, 1, 1.25, 1.5 m.s-1) before (V1) and after a 12-week intervention in 21 adolescents with obesity (11 girls; 13.8 ± 1.4 y). After weight loss, the walking exercise was randomly repeated once without weight reload (V2) and once with a loading corresponding to the total induced weight loss during the program (V2L). Body composition was assessed before and after the intervention. RESULTS Body weight and fat mass decreased in response to the 12-week intervention (p < 0.001), while FFM did not change. The absolute gross Cw (ml.m-1) was higher on V1 compared with V2 at every speed. The absolute net Cw (ml.m-1) was higher on V1 compared to V2L at 0.75 m.s-1 (p = 0.04) and 1 m.s-1 (p = 0.02) and higher on V2L compared with V2 at 1.5 m.s-1 (p = 0.03). Net Cw (ml.m-1.kg-1) on V1 being higher than V2 (p < 0.001), and V2L higher than V2 (p = 0.006). The absolute CHO oxidation (mg.min-1) did not show any condition effect (p = 0.12) while fat utilization was higher on V1 compared to V2 and V2L (p < 0.001). Relative to body weight CHO oxidation was lower on V1 compared to V2 (p = 0.04) and V2L (p = 0.004) while relative to body weight fat oxidation was higher on V1 than V2 (p = 0.002). CONCLUSION Adolescents with obesity might not show an entire rise back to pre-weight loss values of their metabolic cost of walking when weight gain is simulated. These new findings suggest metabolic and physiological adaptations to weight loss of the energy metabolism that remain to be clarified.
Collapse
Affiliation(s)
- D Thivel
- Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Clermont Auvergne University, 63000, Clermont-Ferrand, France.
- International Research Chair Health in Motion, Clermont Auvergne University Foundation, 63000, Clermont-Ferrand, France.
| | - G Ennequin
- Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Clermont Auvergne University, 63000, Clermont-Ferrand, France
- International Research Chair Health in Motion, Clermont Auvergne University Foundation, 63000, Clermont-Ferrand, France
| | - C Lambert
- Biostatistics Unit, DRCI, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - J Siroux
- Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Clermont Auvergne University, 63000, Clermont-Ferrand, France
| | - S Ratel
- Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Clermont Auvergne University, 63000, Clermont-Ferrand, France
| | - A Boscaro
- Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Clermont Auvergne University, 63000, Clermont-Ferrand, France
| | - L Pelissier
- Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Clermont Auvergne University, 63000, Clermont-Ferrand, France
| | - V Julian
- CHU Clermont-Ferrand, Clermont-Ferrand, France; Department of Sport Medicine and Functional and Respiratory Rehabilitation, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - C Cardenoux
- Children Medical Center, 63450, Romagnat, France
| | - M Duclos
- International Research Chair Health in Motion, Clermont Auvergne University Foundation, 63000, Clermont-Ferrand, France
- CHU Clermont-Ferrand, Clermont-Ferrand, France; Department of Sport Medicine and Functional and Respiratory Rehabilitation, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - S Lazzer
- Department of Medicine, School of Sport Sciences, University of Udine, 33058, Udine, Italy
| | - B Pereira
- Biostatistics Unit, DRCI, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Y Boirie
- CSO-CALORIS, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; Department of Human Nutrition, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - L Isacco
- Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Clermont Auvergne University, 63000, Clermont-Ferrand, France
- International Research Chair Health in Motion, Clermont Auvergne University Foundation, 63000, Clermont-Ferrand, France
| |
Collapse
|
2
|
Garbacki N, Willems J, Neutelings T, Lambert C, Deroanne C, Adrian A, Franz M, Maurer M, De Gieter P, Nusgens B, Colige A. Microgravity triggers ferroptosis and accelerates senescence in the MG-63 cell model of osteoblastic cells. NPJ Microgravity 2023; 9:91. [PMID: 38104197 PMCID: PMC10725437 DOI: 10.1038/s41526-023-00339-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 12/01/2023] [Indexed: 12/19/2023] Open
Abstract
In space, cells sustain strong modifications of their mechanical environment. Mechanosensitive molecules at the cell membrane regulate mechanotransduction pathways that induce adaptive responses through the regulation of gene expression, post-translational modifications, protein interactions or intracellular trafficking, among others. In the current study, human osteoblastic cells were cultured on the ISS in microgravity and at 1 g in a centrifuge, as onboard controls. RNAseq analyses showed that microgravity inhibits cell proliferation and DNA repair, stimulates inflammatory pathways and induces ferroptosis and senescence, two pathways related to ageing. Morphological hallmarks of senescence, such as reduced nuclear size and changes in chromatin architecture, proliferation marker distribution, tubulin acetylation and lysosomal transport were identified by immunofluorescence microscopy, reinforcing the hypothesis of induction of cell senescence in microgravity during space flight. These processes could be attributed, at least in part, to the regulation of YAP1 and its downstream effectors NUPR1 and CKAP2L.
Collapse
Affiliation(s)
- Nancy Garbacki
- Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, 4000, Liège, Belgium
| | - Jérôme Willems
- Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, 4000, Liège, Belgium
| | - Thibaut Neutelings
- Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, 4000, Liège, Belgium
| | - Charles Lambert
- Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, 4000, Liège, Belgium
| | - Christophe Deroanne
- Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, 4000, Liège, Belgium
| | - Astrid Adrian
- Airbus Defence and Space, GmbH, 88090, Immenstaad, Germany
| | - Markus Franz
- Airbus Defence and Space, GmbH, 88090, Immenstaad, Germany
| | - Matthias Maurer
- European Space Agency (ESA), European Astronaut Centre (EAC), 51147, Cologne, Germany
| | | | - Betty Nusgens
- Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, 4000, Liège, Belgium
| | - Alain Colige
- Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, 4000, Liège, Belgium.
| |
Collapse
|
3
|
Mathieu S, Lambert C, Fayet F, Couderc M, Beauger M, Malochet S, Pickering ME, Tournadre A, Soubrier M. Comparison of the cardiovascular risk profile of rheumatoid arthritis versus hand osteoarthritis patients. Rheumatol Int 2023; 43:2065-2072. [PMID: 37566254 DOI: 10.1007/s00296-023-05405-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Accepted: 07/23/2023] [Indexed: 08/12/2023]
Abstract
It is clear that there is an increased cardiovascular (CV) risk in rheumatoid arthritis (RA) as a result of systemic inflammation. Hand osteoarthritis (HOA) patients, also have an increased CV risk, but the causes are still debated. Our objective was to compare CV risk factors and risk scores between HOA and RA patients. Thirty-five HOA patients were matched by age (< 3 years) and sex to 35 RA patients in a case-control study. We compared their CV risk profiles and their risk of occurrence of CV events at 10 years using the risk equations SCORE1, SCORE2, and QRISK3. There was a significant increase in SCORE1, SCORE2, but not in QRISK3 in the RA group compared to the HOA group, provided that the multiplication coefficient for RA was applied. This increase was found to no longer be significant for SCORE1 when RA patients have low disease activity (DAS28 ≤ 3.2; n = 8). There was no difference between groups in the frequency of metabolic syndrome, blood pressure, abdominal circumference, body mass index, uricemia, triglyceridemia, HDL cholesterolemia, or pain intensity. Conversely, HOA patients had higher LDL cholesterol and fasting blood glucose levels, in the main analysis and in the subgroup of moderate/high RA activity patients (DAS28 > 3.2; n = 26). We found a higher CV risk in RA compared to HOA patients with moderate/high disease activity. The increased CV risk reported in OA remains to be confirmed in HOA, but these patients appear to have a pro-atherogenic lipid and glycemic profile.
Collapse
Affiliation(s)
- Sylvain Mathieu
- Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, Neuro-Dol, 63000, Clermont-Ferrand, France.
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.
| | - C Lambert
- Unité de Biostatistiques, DRCI, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Françoise Fayet
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Marion Couderc
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Marine Beauger
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Sandrine Malochet
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Marie-Eva Pickering
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Anne Tournadre
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - Martin Soubrier
- Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France
| |
Collapse
|
4
|
Belliveau C, Benhacene-Boudam MK, Juneau D, Olivié D, Barkati M, Delouya G, Taussky D, Lambert C, Beauchemin MC, Menard C. F18-DCFPyL PSMA-PET/CT vs. mpMRI for Localizing the Gross Target Volume for Radiotherapy in Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e368. [PMID: 37785257 DOI: 10.1016/j.ijrobp.2023.06.2464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Local recurrences in prostate cancer (Pca) after radiotherapy generally occur in the site of dominant tumor burden, and recent evidence based on multi parametric (mpMRI) supports tumor-targeted escalation of dose to improve biochemical disease-free survival outcomes. With the recent emergence of prostate cancer targeted radiotracers, we hypothesize that PSMA-PET and mpMRI may not equally depict the pathological gross target volume (pGTV) at risk of recurrence after radiotherapy. MATERIALS/METHODS Subjects who underwent both mpMRI and 18F DCFPyl PSMA-PET/CT prior to radiotherapy were identified from a prospective REB-approved registry. Patients who were naive to radiotherapy and patients with local recurrences were evaluated. Each patient underwent standard of care systematic biopsies prior to imaging and treatment. Sextants from prostate biopsy were analyzed on an independent basis. Per previous published work, pGTV at risk of recurrence was defined as the pathological dominant lesions with peak PCL (percentage core length) involvement and any sextants with ≽ 40% PCL involvement. Each imaging method was analyzed independently to determine spatial correspondence of the visible tumor to pGTV at risk of recurrence. Lesions scored 4-5 (PIRADSv2.1) were identified on mpMRI. For PSMA-PET, regions with uptake higher than the adjacent background with scaling SUVmin-max 0-10 were identified. RESULTS Forty-seven patients with histopathological proven intermediate to high-risk Pca represented the study cohort. Of the 320 sextants, 135 were involved with PCa. Thirty-six percent (17∕47) of patients had a history of prior radiotherapy. PSMA-PET identified the pGTV in 89% (42∕47) of patients, while mpMRI yielded a higher detection rate at 98% (46∕47) (89% vs 98% p = 0.038). The only pGTV not detected on mpMRI was also missed by PSMA-PET, and had received EBRT in 2011. Of the four other pGTVs at risk of recurrence missed by PSMA-PET, three had no history of prior radiotherapy and one was treated with brachytherapy in 2005. Overall, we found no differences in imaging detection rates between previously treated and untreated patients. More detailed volumetric analyses are ongoing and will be presented. CONCLUSION mpMRI may provide superior detection of the pGTV at risk of recurrence in comparison to PSMA-PET. Until further research is completed, clinicians should exercise caution in omitting mpMRI and utilizing PSMA-PET as the sole imaging method for GTV targeting.
Collapse
Affiliation(s)
- C Belliveau
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | | | - D Juneau
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - D Olivié
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - M Barkati
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - G Delouya
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - D Taussky
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - C Lambert
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - M C Beauchemin
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - C Menard
- Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| |
Collapse
|
5
|
Aissaoui D, Bahary JP, Oulmoudne N, Roberge D, Masucci L, Lambert C, Menard C. Symptomatic Posttreatment Edema after Stereotactic Radiotherapy for Intracranial Meningiomas: Patterns and Predictive Factors. Int J Radiat Oncol Biol Phys 2023; 117:e85. [PMID: 37786197 DOI: 10.1016/j.ijrobp.2023.06.836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Symptomatic posttreatment edema (SPTE) is a complication that may develop after radiotherapy for intracranial meningiomas. Our study aims at reviewing rates of SPTE in a large cohort of a single institution and identifying possible predictive factors. MATERIALS/METHODS We retrospectively analyzed data of 293 patients with 304 intracranial meningiomas irradiated at our institution between 2005 and 2018. We evaluated rates of SPTE and investigated numerous factors by univariate and multivariate analysis. Kaplan Meier analysis was used for estimation of actuarial local control and overall survival. RESULTS Median age was 60 years. Meningiomas were treated with fractionated stereotactic radiation therapy (70%), single fraction stereotactic radiosurgery (24%) or fractionated stereotactic radiosurgery (6%). Median imaging follow-up was 60 months, actuarial 10-year local control rate for patients with grade 1 meningiomas who received radiotherapy as definitive treatment was 99%. Local control at 5 years was 94% for grade 1 meningioma, 57% and 53% for grade 2 and 3 respectively. Sixteen patients (5.5%) developed SPTE, median time to onset was 3 months (range, 1-26 months). On univariate analysis, age > 60 years (p > 0.03), pre-treatment peritumoral edema (p = 0.014), medline location (p = 0.018), tumor size > 30 mm (p = 0.015) and grade 2 histology (p = 0.03) were predictive of SPTE. On multivariate analysis, only tumor location and size remained statistically significant. CONCLUSION Based on our results, patients at high risk of SPTE can be identified based on patient and tumor characteristics. The best treatment technique in high-risk patients is yet to be defined.
Collapse
Affiliation(s)
- D Aissaoui
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Montreal, QC, Canada
| | - J P Bahary
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Montreal, QC, Canada
| | - N Oulmoudne
- Department of Radiation Oncology, Hopital affilié universitaire de Trois-rivieres, Trois rivieres, Quebec, Trois rivieres, QC, Canada
| | - D Roberge
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Montreal, QC, Canada
| | - L Masucci
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Montreal, QC, Canada
| | - C Lambert
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Montreal, QC, Canada
| | - C Menard
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Montreal, QC, Canada
| |
Collapse
|
6
|
Gibson-Helm M, Slater T, MacDonald EJ, Stevenson K, Adcock A, Geller S, Parag V, Lambert C, Bennett M, Hibma M, Sykes P, Saville M, Hawkes D, Stanton JA, Clueard MA, Jelley G, Lawton B. Te Ara Waiora-Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial. PLoS One 2023; 18:e0280643. [PMID: 36952546 PMCID: PMC10035917 DOI: 10.1371/journal.pone.0280643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 12/07/2022] [Indexed: 03/25/2023] Open
Abstract
BACKGROUND Cervical cancer is caused by high-risk types of human papillomavirus (HPV). Testing for high-risk HPV is a more sensitive screening method than cervical cytology for detecting cervical changes that may lead to cancer. Consistent with recent evidence of efficacy and acceptability, Aotearoa New Zealand plans to introduce HPV testing as the primary approach to screening, replacing cervical cytology, from mid-2023. Any equitable cervical screening programme must be effective across a diverse population, including women that the current programme fails to reach, particularly Māori and those in rural areas. Currently, we do not know the best model for implementing an equitable HPV self-testing screening programme. METHODS This implementation trial aims to assess whether a universal offer of HPV self-testing (offered to all people eligible for cervical screening) achieves non-inferior screening coverage (equal) to a universal offer of cervical cytology alone (the present programme). The study population is all people aged from 24.5 to 70 years due for cervical screening in a 12-month period (including those whose screening is overdue or who have never had screening). A range of quantitative and qualitative secondary outcomes will be explored, including barriers and facilitators across screening and diagnostic pathways. This study takes place in Te Tai Tokerau/Northland which covers a diverse range of urban and rural areas and has a large Indigenous Māori population. A total of fourteen practices will be involved. Seven practices will offer HPV self-testing universally to approximately 2800 women and will be compared to seven practices providing routine clinical care (offer of cervical cytology) to an approximately equal number of women. DISCUSSION This trial will answer important questions about how to implement an equitable, high-quality, effective national programme offering HPV self-testing as the primary screening method for cervical cancer prevention. TRIAL REGISTRATION Prospectively registered with the Australian New Zealand Clinical Trials Registry 07/12/2021: ACTRN12621001675819.
Collapse
Affiliation(s)
- Melanie Gibson-Helm
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | - Tania Slater
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | - Evelyn J MacDonald
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | - Kendall Stevenson
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | - Anna Adcock
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | - Stacie Geller
- National Center of Excellence in Women's Health, University of Illinois, Chicago, IL, United States of America
| | - Varsha Parag
- National Institute for Health Innovation, University of Auckland, Auckland, New Zealand
| | - Charles Lambert
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | - Matthew Bennett
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | - Merilyn Hibma
- Department of Pathology, University of Otago, Dunedin, New Zealand
| | - Peter Sykes
- Christchurch Hospital and University of Otago, Canterbury, New Zealand
| | - Marion Saville
- Australian Centre for the Prevention of Cervical Cancer, Melbourne, Australia
| | - David Hawkes
- Australian Centre for the Prevention of Cervical Cancer, Melbourne, Australia
| | - Jo-Ann Stanton
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| | | | - Grahame Jelley
- Mahitahi Hauora Primary Health Entity, Northland, New Zealand
| | - Bev Lawton
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand
| |
Collapse
|
7
|
Belliveau C, Barkati M, Delouya G, Taussky D, Beauchemin MC, Lambert C, Beaulieu L, Beliveau-Nadeau D, Nicolas B, Carrier JF, Vigneault E, Ménard C. Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial. Radiat Oncol 2022; 17:203. [PMID: 36494834 PMCID: PMC9733116 DOI: 10.1186/s13014-022-02173-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 11/30/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND For patients with a higher burden of localized prostate cancer, radiation dose escalation with brachytherapy boosts have improved cancer control outcomes at the cost of urinary toxicity. We hypothesize that a focal approach to brachytherapy boosts targeting only grossly visualized tumor volumes (GTV) combined with stereotactic radiotherapy will improve quality of life (QoL) outcomes without compromising cancer control. METHODS 150 patients with intermediate or high-risk prostate cancer will be enrolled and randomized 1:1 in a cohort multiple randomized clinical trial phase 2 design. Patients are eligible if planned for standard-of-care (SOC) high dose rate (HDR) brachytherapy boost to radiotherapy (RT) with GTVs encompassing < 50% of the prostate gland. Those randomly selected will be offered the experimental treatment, consisting of focal HDR brachytherapy boost (fBT) of 13-15 Gy in 1 fraction followed by stereotactic radiotherapy (sRT) 36.25-40 Gy in 5 fractions to the prostate (+/- 25 Gy to the elective pelvis) delivered every other day. The primary endpoint is to determine if fBTsRT is superior to SOC by having fewer patients experience a minimally important decline (MID) in urinary function as measured by EPIC-26 at 1 and 2 years. Secondary endpoints include rates of toxicity measured by Common Terminology Criteria for Adverse Events (CTCAE), and failure-free survival outcomes. DISCUSSION This study will determine whether a novel approach for the treatment of localized prostate cancer, fBTsRT, improves QoL and merits further evaluation. Trial registration This trial was prospectively registered in ClinicalTrials.gov as NCT04100174 as a companion to registry NCT03378856 on September 24, 2019.
Collapse
Affiliation(s)
- C. Belliveau
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - M. Barkati
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - G. Delouya
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - D. Taussky
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - M. C. Beauchemin
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - C. Lambert
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - L. Beaulieu
- grid.23856.3a0000 0004 1936 8390Radiation Oncology, Centre universitaire de Québec, Université Laval, 2705 Laurier Boulevard, Quebec City, QC G1V 4G2 Canada
| | - D. Beliveau-Nadeau
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - B. Nicolas
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - J. F. Carrier
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| | - E. Vigneault
- grid.23856.3a0000 0004 1936 8390Radiation Oncology, Centre universitaire de Québec, Université Laval, 2705 Laurier Boulevard, Quebec City, QC G1V 4G2 Canada
| | - C. Ménard
- grid.410559.c0000 0001 0743 2111Radiation Oncology, CHUM - Centre Hospitalier de l’Université de Montréal, 900 Saint Denis St, Montreal, QC H2X 0A9 Canada
| |
Collapse
|
8
|
Lemaitre F, Chakrama F, O’Grady T, Peulen O, Rademaker G, Deward A, Chabot B, Piette J, Colige A, Lambert C, Dequiedt F, Habraken Y. The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress. Nucleic Acids Res 2022; 50:12768-12789. [PMID: 36477312 PMCID: PMC9825188 DOI: 10.1093/nar/gkac1130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 10/31/2022] [Accepted: 11/10/2022] [Indexed: 12/13/2022] Open
Abstract
Genotoxic agents, that are used in cancer therapy, elicit the reprogramming of the transcriptome of cancer cells. These changes reflect the cellular response to stress and underlie some of the mechanisms leading to drug resistance. Here, we profiled genome-wide changes in pre-mRNA splicing induced by cisplatin in breast cancer cells. Among the set of cisplatin-induced alternative splicing events we focused on COASY, a gene encoding a mitochondrial enzyme involved in coenzyme A biosynthesis. Treatment with cisplatin induces the production of a short isoform of COASY lacking exons 4 and 5, whose depletion impedes mitochondrial function and decreases sensitivity to cisplatin. We identified RBM39 as a major effector of the cisplatin-induced effect on COASY splicing. RBM39 also controls a genome-wide set of alternative splicing events partially overlapping with the cisplatin-mediated ones. Unexpectedly, inactivation of RBM39 in response to cisplatin involves its interaction with the AP-1 family transcription factor c-Jun that prevents RBM39 binding to pre-mRNA. Our findings therefore uncover a novel cisplatin-induced interaction between a splicing regulator and a transcription factor that has a global impact on alternative splicing and contributes to drug resistance.
Collapse
Affiliation(s)
| | | | - Tina O’Grady
- Laboratory of Gene Expression and Cancer, GIGA-Molecular Biology of Diseases, B34, University of Liège, Liège 4000, Belgium
| | - Olivier Peulen
- Metastasis Research Laboratory, GIGA-Cancer, B23, University of Liège, Liège 4000, Belgium
| | - Gilles Rademaker
- Metastasis Research Laboratory, GIGA-Cancer, B23, University of Liège, Liège 4000, Belgium
| | - Adeline Deward
- Laboratory of Virology and Immunology, GIGA-Molecular Biology of Diseases, B34, University of Liège, Liège 4000, Belgium
| | - Benoit Chabot
- Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences. Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Jacques Piette
- Laboratory of Virology and Immunology, GIGA-Molecular Biology of Diseases, B34, University of Liège, Liège 4000, Belgium
| | - Alain Colige
- Laboratory of Connective Tissues Biology, GIGA-Cancer, B23, University of Liège, Liège 4000, Belgium
| | - Charles Lambert
- Laboratory of Connective Tissues Biology, GIGA-Cancer, B23, University of Liège, Liège 4000, Belgium
| | - Franck Dequiedt
- Correspondence may also be addressed to Franck Dequiedt. Tel: +32 366 9028;
| | - Yvette Habraken
- To whom correspondence should be addressed. Tel: +32 4 366 2447; Fax: +32 4 366 4198;
| |
Collapse
|
9
|
Meunier M, Chapuis E, Humeau A, Lambert C, Auriol D, Scandolera A, Reynaud R. 523 Targeting SDF-1 as an efficient strategy to resolve skin hyperpigmentation issues with Himanthalia elongata extract. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
10
|
Meunier M, Chapuis E, Godbille S, Brooks J, Carolan H, Lambert C, Sennelier B, Scandolera A, Reynaud R. 249 Reduction of scalp dryness and white flakes production for emotional improvement. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
11
|
Lambert C, Authier M, Blanchard A, Dorémus G, Laran S, Van Canneyt O, Spitz J. Delayed response to environmental conditions and infra-seasonal dynamics of the short-beaked common dolphin distribution. R Soc Open Sci 2022; 9:220379. [PMID: 36465685 PMCID: PMC9709568 DOI: 10.1098/rsos.220379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 11/06/2022] [Indexed: 06/17/2023]
Abstract
Cetaceans adjust their distribution and abundance to encountered conditions across years and seasons, but we poorly understand such small-scale changes for many species, especially in winter. Crucial challenges confront some populations during this season, such as the high levels of fisheries-induced mortality faced by the common dolphin (Delphinus delphis) in the Northeast Atlantic shelves. For such species, understanding the winter fine-scale dynamics is crucial. We aimed to identify the dolphin distribution drivers during the winters of 2020 and 2021, with a focus on determining the lag between changes in oceanographic conditions and dolphin distribution. The changes were related to temporal delays specific to the nature and cascading effects that oceanographic processes had on the trophic chain. By determining the most important conditions and lags to dolphin distributions, we shed light on the poorly understood intrusions of dolphins within coastal waters during winter: they displayed a strong preference for the coastal-shelf waters front and extensively followed its spatial variations, with their overall densities increasing over the period and peaking in March-April. The results presented here provide invaluable information on the winter distribution dynamics and should inform management decisions to help reduce the unsustainable mortalities of this species in the by-catch of fisheries.
Collapse
Affiliation(s)
- C. Lambert
- Observatoire Pelagis UAR 3462 CNRS-LRUniv, 5 allée de l’Océan, La Rochelle 17000, France
- Centre d’Etudes Biologiques de Chizé UMR 7372 CNRS-LRUniv, 405 Rte de Prissé la Charrière, Villiers-en-bois 79360, France
- Littoral ENvironnement et Sociétés UMR 7266 CNRs-LRUniv, 2 Rue Olympe de Gouge, La Rochelle 17000, France
| | - M. Authier
- Observatoire Pelagis UAR 3462 CNRS-LRUniv, 5 allée de l’Océan, La Rochelle 17000, France
| | - A. Blanchard
- Observatoire Pelagis UAR 3462 CNRS-LRUniv, 5 allée de l’Océan, La Rochelle 17000, France
| | - G. Dorémus
- Observatoire Pelagis UAR 3462 CNRS-LRUniv, 5 allée de l’Océan, La Rochelle 17000, France
| | - S. Laran
- Observatoire Pelagis UAR 3462 CNRS-LRUniv, 5 allée de l’Océan, La Rochelle 17000, France
| | - O. Van Canneyt
- Observatoire Pelagis UAR 3462 CNRS-LRUniv, 5 allée de l’Océan, La Rochelle 17000, France
| | - J. Spitz
- Observatoire Pelagis UAR 3462 CNRS-LRUniv, 5 allée de l’Océan, La Rochelle 17000, France
- Centre d’Etudes Biologiques de Chizé UMR 7372 CNRS-LRUniv, 405 Rte de Prissé la Charrière, Villiers-en-bois 79360, France
| |
Collapse
|
12
|
Martinez C, Meterissian S, Fleiszer D, Tremblay F, Meguerditchian A, Saidi A, Lambert C, Panet-Raymond V, David M, Hijal T. Targeted Intraoperative Radiotherapy (TARGIT) during Breast-Conserving Surgery for Patients with Early-Stage Breast Cancer: A Phase II Prospective Trial. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Sabour M, Chalard A, Merlin E, Lambert C, Verdan M, Dauphin C. Pericarditis in children: A 10-year descriptive study and evaluation of prognostic factors. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2022.07.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
14
|
Noelle J, Mayet V, Couzi L, Thierry A, Bertrand D, Lambert C, Heng A, Rouzaire P, Garrouste C. Impact du maintien des inhibiteurs de la calcineurine après arrêt fonctionnel du transplant rénal sur le devenir du nouveau greffon, une étude rétrospective multicentrique avec score de propension. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
15
|
Ares-Blanco J, Pujante-Alarcón P, Lambert C, Morales-Sánchez P, Delgado-Álvarez E, Menéndez-Torre EL. Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus. Rev Clin Esp 2022; 222:S2254-8874(22)00052-2. [PMID: 35817680 DOI: 10.1016/j.rceng.2022.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Accepted: 03/04/2022] [Indexed: 10/17/2022]
Abstract
OBJECTIVES This work aims to determine the real-life anthropometric and analytical benefits of adding subcutaneous semaglutide to previous insulin treatment in patients with type 2 diabetes. METHODS This is a descriptive, retrospective, open-label study describing the clinical and anthropometric characteristics of 117 patients diagnosed with type 2 diabetes followed-up on in the Endocrinology and Nutrition outpatient clinic of the Hospital Universitario Central de Asturias for 53 weeks after starting treatment with subcutaneous semaglutide (October-December 2019). All patients were on previous insulin treatment with or without oral antidiabetics. RESULTS Of the 117 initial patients, 17 did not complete the study due to adverse effects (nausea, vomiting), the physician's decision, or loss to follow-up. Twelve months (week 53) after starting semaglutide, there was a decrease in HbA1c of 0.74% (95% CI 0.59-1.14, p < 0.05) as well as 3.61 kg of weight loss (95% CI 2.30-4.92, p < 0.05) and a decline in total insulin of 15.88 IU (95% CI 10.98-20.74, p < 0.05) from baseline figures. In patients without prior GLP-1 receptor analogs (GLP-1ra), the effect in terms of a reduction in HbA1c, weight, and the total insulin dose was statistically significant. However, in patients pre-treated with GLP-1ra only had improvements in terms of weight loss. No serious adverse events were observed. CONCLUSIONS The addition of subcutaneous semaglutide to prior insulin treatment with or without oral antidiabetics safely led to a decrease in HbA1c, weight, and the insulin dose. This effect is greater in GLP-1ra naive patients.
Collapse
Affiliation(s)
- J Ares-Blanco
- Servicio de Endocrinología y Nutrición, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Grupo ENDO, Oviedo, Asturias, Spain; Departamento de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain.
| | - P Pujante-Alarcón
- Servicio de Endocrinología y Nutrición, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Grupo ENDO, Oviedo, Asturias, Spain
| | - C Lambert
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Grupo ENDO, Oviedo, Asturias, Spain; Universidad de Barcelona, Barcelona, Spain
| | - P Morales-Sánchez
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Grupo ENDO, Oviedo, Asturias, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain
| | - E Delgado-Álvarez
- Servicio de Endocrinología y Nutrición, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Grupo ENDO, Oviedo, Asturias, Spain; Departamento de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain
| | - E L Menéndez-Torre
- Servicio de Endocrinología y Nutrición, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Grupo ENDO, Oviedo, Asturias, Spain; Departamento de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain
| |
Collapse
|
16
|
Ares-Blanco J, Pujante-Alarcón P, Lambert C, Morales-Sánchez P, Delgado-Álvarez E, Menéndez-Torre E. Efectos en vida real de la adición de semaglutida subcutánea semanal al tratamiento con insulina en diabetes mellitus tipo 2. Rev Clin Esp 2022. [DOI: 10.1016/j.rce.2022.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Laquet P, Pradère B, Francois M, Ravel A, Lambert C, Guy L. Résultats périopératoires de la radiofréquence sur les petites tumeurs du rein : complications, impact sur la fonction rénale et résultats oncologiques. Prog Urol 2022; 32:551-557. [DOI: 10.1016/j.purol.2022.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 03/14/2022] [Accepted: 04/05/2022] [Indexed: 10/18/2022]
|
18
|
Janssens A, Selleslag D, Depaus J, Beguin Y, Lambert C. Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society. Acta Clin Belg 2022; 77:470-483. [PMID: 33635747 DOI: 10.1080/17843286.2021.1876310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The Belgian Hematology Society (BHS) updated the 2013 guidelines for diagnosis and treatment of primary immune thrombocytopenia (ITP) [1]. As knowledge about ITP pathophysiology is increasing, the mode of action of old therapies is better understood and novel drugs are introduced to target more specific pathways.Corticosteroids with or without intravenous immunoglobulins (IgIV) remain the first-line treatment. According to the updated international guidelines a short course of corticosteroids rather than a prolonged treatment has to be recommended. The same guidelines stress that consequent therapies as thrombopoietic agents (TPO-RAs) and rituximab should be available independent of duration of ITP.Although the majority of recommendations is based on very low-quality evidence, it is strongly advised to individualize the ITP management taking patient values. and preferences in account. The main treatment goal in all ITP patients must be to maintain a safe platelet count to prevent or stop bleeding with a minimum of toxicity and not to normalize the platelet count.
Collapse
Affiliation(s)
- A. Janssens
- Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
| | - D. Selleslag
- Department of Hematology, AZ Sint-Jan Brugge, Brugge, Belgium
| | - J. Depaus
- Department of Hematology, CHU UCL Namur, Yvoir, Belgium
| | - Y. Beguin
- Department of Hematology, Centre Hospitalier Universitaire Liège, Liège, Belgium
| | - C. Lambert
- Department of Hematology, Cliniques Universitaire St Luc, Bruxelles, Belgium
| |
Collapse
|
19
|
Gibert S, Edel-Hermann V, Gautheron E, Gautheron N, Sol JM, Capelle G, Galland R, Bardon-Debats A, Lambert C, Steinberg C. First Report of Fusarium avenaceum, Fusarium oxysporum, Fusarium redolens, and Fusarium solani Causing Root Rot in Pea in France. Plant Dis 2022; 106:1297. [PMID: 35316076 DOI: 10.1094/pdis-04-21-0833-pdn] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- S Gibert
- Agroécologie, AgroSup Dijon, INRAE, Univ. Bourgogne, Univ. Bourgogne Franche-Comté, F-21000 Dijon, France
- Société BONDUELLE SAS, Rue Nicolas Appert - BP 17, 59653 Villeneuve d'Ascq - CEDEX, France
| | - V Edel-Hermann
- Agroécologie, AgroSup Dijon, INRAE, Univ. Bourgogne, Univ. Bourgogne Franche-Comté, F-21000 Dijon, France
| | - E Gautheron
- Agroécologie, AgroSup Dijon, INRAE, Univ. Bourgogne, Univ. Bourgogne Franche-Comté, F-21000 Dijon, France
| | - N Gautheron
- Agroécologie, AgroSup Dijon, INRAE, Univ. Bourgogne, Univ. Bourgogne Franche-Comté, F-21000 Dijon, France
| | - J-M Sol
- Société BONDUELLE SAS, Rue Nicolas Appert - BP 17, 59653 Villeneuve d'Ascq - CEDEX, France
| | - G Capelle
- Société BONDUELLE SAS, Rue Nicolas Appert - BP 17, 59653 Villeneuve d'Ascq - CEDEX, France
| | - R Galland
- Société BONDUELLE SAS, Rue Nicolas Appert - BP 17, 59653 Villeneuve d'Ascq - CEDEX, France
| | - A Bardon-Debats
- Société BONDUELLE SAS, Rue Nicolas Appert - BP 17, 59653 Villeneuve d'Ascq - CEDEX, France
| | - C Lambert
- Société BONDUELLE SAS, Rue Nicolas Appert - BP 17, 59653 Villeneuve d'Ascq - CEDEX, France
| | - C Steinberg
- Agroécologie, AgroSup Dijon, INRAE, Univ. Bourgogne, Univ. Bourgogne Franche-Comté, F-21000 Dijon, France
| |
Collapse
|
20
|
Poinard S, Garcin T, Trone MC, Mentek M, Lambert C, Bonjean P, Renault D, Thuret G, Gain P, Gauthier AS. Objective measurement of adherence to topical steroid medication after penetrating keratoplasty using an electronic monitoring aid: A pilot study. Digit Health 2022; 8:20552076221121155. [PMID: 36133001 PMCID: PMC9483967 DOI: 10.1177/20552076221121155] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 08/05/2022] [Indexed: 12/02/2022] Open
Abstract
Objectives Corneal transplantation is the most common transplant worldwide and its
success critically depends on the management of corneal graft rejection
through topical steroid therapy during the first 12 months after surgery.
There is currently no published data on adherence after keratoplasty. This
pilot study aims to explore the adherence to topical steroid after
penetrating keratoplasty using a smart electronic device. Methods Thirty patients undergoing penetrating keratoplasty were included to evaluate
the adherence to topical dexamethasone medication for 12 months after
surgery. Patients received the usual post-transplantation treatment (topical
dexamethasone) and follow-up after surgery (day 15, months 1, 2, 3, 4, 5, 6,
9, and 12). Adherence to treatment was monitored using the KaliJAR device
(Kali Care, Santa Clara, CA, USA), which recorded the number of single-dose
units (SDU) discarded. At control visits, data recorded by the device were
compared to the manually count of SDU. Adherence ratio and individual
adherence curve were explored for all patients. Results Data from 27 patients showed a high agreement between adherence ratio
calculated based on the device data and obtained from manual counting of the
discarded SDU (intraclass coefficient correlation of 0.87 [95% CI:
0.738–0.938]). Mean adherence to the treatment over the 12-month study
period was 95.2 ± 4%. Conclusions Adherence to topical dexamethasone for 12 months after corneal
transplantation was high. The connected device was able to record accurately
the discarded SDU. This approach would be a particular interest in the early
identification and personalized follow-up of poorly adherent patients.
Collapse
Affiliation(s)
- Sylvain Poinard
- Corneal Graft Biology, Engineering and Imaging Laboratory, Jean Monnet University, Saint-Etienne, France
- Ophthalmology Department, University Hospital, Saint-Etienne, France
| | - Thibaud Garcin
- Corneal Graft Biology, Engineering and Imaging Laboratory, Jean Monnet University, Saint-Etienne, France
- Ophthalmology Department, University Hospital, Saint-Etienne, France
| | - Marie-Caroline Trone
- Corneal Graft Biology, Engineering and Imaging Laboratory, Jean Monnet University, Saint-Etienne, France
- Ophthalmology Department, University Hospital, Saint-Etienne, France
| | - Marielle Mentek
- Corneal Graft Biology, Engineering and Imaging Laboratory, Jean Monnet University, Saint-Etienne, France
| | - Charles Lambert
- Ophthalmology Department, University Hospital, Saint-Etienne, France
| | - Paul Bonjean
- Ophthalmology Department, University Hospital, Saint-Etienne, France
| | - Didier Renault
- Corneal Graft Biology, Engineering and Imaging Laboratory, Jean Monnet University, Saint-Etienne, France
| | - Gilles Thuret
- Corneal Graft Biology, Engineering and Imaging Laboratory, Jean Monnet University, Saint-Etienne, France
- Ophthalmology Department, University Hospital, Saint-Etienne, France
| | - Philippe Gain
- Corneal Graft Biology, Engineering and Imaging Laboratory, Jean Monnet University, Saint-Etienne, France
- Ophthalmology Department, University Hospital, Saint-Etienne, France
| | | |
Collapse
|
21
|
Lambert C, Mahévas T, Gobert D, Bravetti M, Radzik A, Poujol-Robert A, Ghrenassia E, Fain O. [Epigastric pain]. Rev Med Interne 2021; 43:260-261. [PMID: 34509317 DOI: 10.1016/j.revmed.2021.07.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 03/07/2021] [Accepted: 07/18/2021] [Indexed: 10/20/2022]
Affiliation(s)
- C Lambert
- Service de médecine interne, Sorbonne université, hôpital Saint-Antoine, AP-HP, Paris, France
| | - T Mahévas
- Service de médecine interne, Sorbonne université, hôpital Saint-Antoine, AP-HP, Paris, France.
| | - D Gobert
- Service de médecine interne, Sorbonne université, hôpital Saint-Antoine, AP-HP, Paris, France
| | - M Bravetti
- Service de radiologie interventionnelle, Sorbonne université, hôpital de la Pitié-Salpêtrière, Paris, France
| | - A Radzik
- Service de radiologie, Sorbonne université, hôpital Saint-Antoine, Paris, France
| | - A Poujol-Robert
- Service d'hépatologie, Sorbonne université, hôpital Saint-Antoine, Paris, France
| | - E Ghrenassia
- Service de médecine interne, Sorbonne université, hôpital Saint-Antoine, AP-HP, Paris, France
| | - O Fain
- Service de médecine interne, Sorbonne université, hôpital Saint-Antoine, AP-HP, Paris, France
| |
Collapse
|
22
|
Rais F, Tsui J, Faye M, Daianska A, Lambert C, David M, Panet-Raymond V, Azoulay M, Saidi A, Hijal T. PO-1115 Extreme weekly locoregional hypofractionated radiation in elderly with non-metastatic breast cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07566-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
23
|
Marques A, Beze S, Lambert C, Bonamy L, de Chazeron I, Rieu I, Chiambaretta F, Durif F. Psycho-sensory modalities of visual hallucinations and illusions in Parkinson's disease. Rev Neurol (Paris) 2021; 177:1228-1236. [PMID: 34238577 DOI: 10.1016/j.neurol.2021.04.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 04/10/2021] [Accepted: 04/16/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Visual illusions (VI) in Parkinson's disease (PD) are generally considered part of the prodrome towards fully formed visual hallucinations (VH), and classified as minor hallucinations. However, this sequential relationship has not been clearly demonstrated and very little is known about the specific phenomenology of VI in regards to VH. We aimed to describe and compare psycho-sensory modalities associated with VI and VH in PD patients. METHODS PD patients with VI (PD-I, n=26) and VH (PD-H, n=28) were included in this case-controlled study. We compared qualitative and quantitative psycho-sensory modalities of VI and VH using the PsychoSensory hAllucinations Scale (PSAS), and demographical and clinical features of each group. RESULTS PD-I perceptions were more often colored blots (P=0.05) or objects (P=0.005) compared to PD-H. Conversely, PD-H perceptions were more often described as animals (P<0.001), occurring at night (P=0.03) compared to PD-I. The experienced phenomena were more frequent in PD-H (P=0.02), and lasted longer (P=0.02) than for PD-I, but no between-group difference was observed for other repercussion factors including negative aspect, conviction, impact, controllable nature of the perception. Passage hallucinations and sense of presence were observed in both groups with similar frequencies (respectively P=0.60 and P=0.70). Multivariate analysis adjusting for disease severity or duration confirmed these results. CONCLUSION VI and VH in PD have different qualitative sensory modalities, with similar quantitative repercussion for patients, and similar association with modalities such as "sense of presence and passage hallucinations", in contrast to the generally accepted classification of VI as minor VH. REGISTRATION NUMBER: clinicaltrials.gov number NCT03454269.
Collapse
Affiliation(s)
- A Marques
- Université Clermont-Auvergne, EA7280, neurology department, Clermont-Ferrand university hospital, Clermont-Ferrand, France.
| | - S Beze
- Université Clermont-Auvergne, EA7280, neurology department, Clermont-Ferrand university hospital, Clermont-Ferrand, France; Ophtalmology department, Clermont-Ferrand university hospital, Clermont-Ferrand, France
| | - C Lambert
- Biostatistics department, Clermont-Ferrand university hospital, Clermont-Ferrand, France
| | - L Bonamy
- Université Clermont-Auvergne, EA7280, neurology department, Clermont-Ferrand university hospital, Clermont-Ferrand, France
| | - I de Chazeron
- Université Clermont-Auvergne, EA7280, psychiatry department, Clermont-Ferrand university hospital, Clermont-Ferrand, France
| | - I Rieu
- Université Clermont-Auvergne, EA7280, neurology department, Clermont-Ferrand university hospital, Clermont-Ferrand, France
| | - F Chiambaretta
- Ophtalmology department, Clermont-Ferrand university hospital, Clermont-Ferrand, France
| | - F Durif
- Université Clermont-Auvergne, EA7280, neurology department, Clermont-Ferrand university hospital, Clermont-Ferrand, France
| |
Collapse
|
24
|
Arnal ME, Denis S, Uriot O, Lambert C, Holowacz S, Paul F, Kuylle S, Pereira B, Alric M, Blanquet-Diot S. Impact of oral galenic formulations of Lactobacillus salivarius on probiotic survival and interactions with microbiota in human in vitro gut models. Benef Microbes 2021; 12:75-90. [PMID: 34109893 DOI: 10.3920/bm2020.0187] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Health benefits of probiotics in humans essentially depend on their ability to survive during gastrointestinal (GI) transit and to modulate gut microbiota. To date, there is few data on the impact of galenic formulations of probiotics on these parameters. Even if clinical studies remain the gold standard to evaluate the efficacy of galenic forms, they stay hampered by technical, ethical and cost reasons. As an alternative approach, we used two complementary in vitro models of the human gut, the TNO gastrointestinal (TIM-1) model and the Artificial Colon (ARCOL), to study the effect of three oral formulations of a Lactobacillus salivarius strain (powder, capsule and sustained-release tablet) on its viability and interactions with gut microbiota. In the TIM-1 stomach, no or low numbers of bacteria were respectively released from the capsule and tablet, confirming their gastro-resistance. The capsule was disintegrated in the jejunum on average 76 min after administration while the core of sustained-release tablet was still intact at the end of digestion. Viability in TIM-1 was significantly influenced by the galenic form with survival percentages of 0.003±0.004%, 2.8±0.6% and 17.0±1.8% (n=3) for powder, capsule and tablet, respectively. In the ARCOL, the survival of the strain tended to be higher in the post-treatment phase with the tablet compared to capsule, but gut microbiota composition and activity were not differently modulated by the two formulations. In conclusion, the sustained-release tablet emerged as the formulation that most effectively preserved viability of the tested strain during GI passage. This study highlights the usefulness of in vitro gut models for the pre-screening of probiotic pharmaceutical forms. Their use could also easily be extended to the evaluation of the effects of food matrices and age on probiotic survival and activity during GI transit.
Collapse
Affiliation(s)
- M E Arnal
- Université Clermont Auvergne, UMR 454 MEDIS, Microbiologie Environnement Digestif et Santé, 28 place Henri Dunant, 63000 Clermont-Ferrand, France
| | - S Denis
- Université Clermont Auvergne, UMR 454 MEDIS, Microbiologie Environnement Digestif et Santé, 28 place Henri Dunant, 63000 Clermont-Ferrand, France
| | - O Uriot
- Université Clermont Auvergne, UMR 454 MEDIS, Microbiologie Environnement Digestif et Santé, 28 place Henri Dunant, 63000 Clermont-Ferrand, France
| | - C Lambert
- University Hospital Clermont-Ferrand, Biostatistics Units, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - S Holowacz
- PiLeJe Industrie, Parc Naturopôle, Les Tiolans 03800 Saint-Bonnet de Rochefort, France
| | - F Paul
- Genibio, Le Pradas, ZI du Couserans, 09190 Lorp-Sentaraille, France
| | - S Kuylle
- Genibio, Le Pradas, ZI du Couserans, 09190 Lorp-Sentaraille, France
| | - B Pereira
- University Hospital Clermont-Ferrand, Biostatistics Units, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - M Alric
- Université Clermont Auvergne, UMR 454 MEDIS, Microbiologie Environnement Digestif et Santé, 28 place Henri Dunant, 63000 Clermont-Ferrand, France
| | - S Blanquet-Diot
- Université Clermont Auvergne, UMR 454 MEDIS, Microbiologie Environnement Digestif et Santé, 28 place Henri Dunant, 63000 Clermont-Ferrand, France
| |
Collapse
|
25
|
Darmant N, Fayet F, Lambert C, Pereira B, Rodere M, Fan A, Soubrier M, Duclos M. POS1475-HPR EFFECT OF ARGENTINE TANGO PRACTICE ON TOTAL PHYSICAL ACTIVITY TIME IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM: A PILOT STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Most patients with chronic inflammatory rheumatism (CIR) have a physical activity (PA) level below recommendations [1,2]. Currently, adapted structures offer a range of activities supervised by adapted physical activity educators. To the best of our knowledge, Argentinean tango is not yet offered in these structures.Objectives:The objective of this pilot study was to study the effect of 24 consecutive sessions of Argentinean tango on the total PA level in patients with CIR, including rheumatoid arthritis (RA) and spondyloarthritis (AS).Methods:In this controlled, randomized, open-label, clinical trial with two parallel arms, patients were required to attend two tango sessions per week, 48 sessions from 0 (M0) to 6 months (M6) for the intervention group (IG) and 24 sessions from 3 months (M3) to M6 for the control group (CG). Total PA time was measured at M3 using the Global Physical Activity Questionnaire (GPAQ) [3].Results:A total of 27 patients (23 women) were included, including 15 with RA and 12 with AS. Mean age was 59 ± 12 years, and median disease duration was 10 years (IQR: 3-19). The majority of patients had background treatment (conventional and/or biological). At M3, 22 patients could be evaluated (11 GC patients and 11 GI patients), as 3 patients were lost to follow-up and 2 were unable to come in due to health or professional reasons. The 11 GI patients attended a median of 16 sessions (IQR: 8-22), i.e., approximately one session per week. At M3, the total PA time was not increased, regardless of the measurement method, GPAQ questionnaire (effect size and 95% confidence interval (CI): 0.03 [-0.60; 0.67], p=0.91) or accelerometer (effect size and 95% CI: 0.43 [-0.37; 1.24], p=0.26), and regardless of the intensity of the PA. No significant change was found for sedentary time, disease activity, fatigue, or anxiety. However, improvements were found in body appreciation as assessed by the Body Appreciation Scale 2 questionnaire (p=0.016), balance (p=0.053), wrist bending angle (p=0.092), and shoulder amplitude (p=0.093). The few participants in this study is explained by the geographic distance of the classes and their homes, the lack of availability of patients in professional activity, fatigue, or not liking dance (mainly among men).Conclusion:The results of this pilot study suggest that one Argentinean tango session per week in CIR patients is more achievable than two sessions as originally planned. As the practice of classes in hospitals is constrained due to geographic distance, the sessions could be offered in adapted structures. Nevertheless, our pilot study shows that the Argentinean tango is beneficial for body appreciation in patients with CIR. A qualitative study is needed to better understand these effects.References:[1]Haute Autorité de Santé (2007). Rheumatoid arthritis: therapeutic aspects excluding drugs and surgery - medico-social and organizational aspects. Professional recommendations service - Medical-economic evaluation and public health service.[2]Haute Autorité de Santé (2008). Spondylarthritis: guide - long-term condition. Good Professional Practices Department - Communication Department.[3] Cleland CL, Hunter RF, Kee F, Cupples ME, Sallis JF, Tully MA. (2014 Dec). Validity of the global physical activity questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. BMC Public Health. 10;14:1255. doi: 10.1186/1471-2458-14-1255.Disclosure of Interests:None declared
Collapse
|
26
|
Glaab F, Lambert C, Engel V. Optically Induced Charge Transfer in Organic Mixed-Valence Systems: Wave Packet Dynamics and Femtosecond Transient Spectroscopy. J Phys Chem A 2021; 125:4114-4125. [PMID: 33960780 DOI: 10.1021/acs.jpca.1c01476] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We theoretically study the dynamics of charge transfer induced by femtosecond laser-pulse excitation. Models involving coupled electronic states of symmetrically bridged organic mixed-valence molecules are investigated, where the motion proceeds along two reaction coordinates. Linear absorption spectra of two species that differ in the energetical position of the bridge, relative to acceptor and donor states, are determined and compared to experimental results. From the wave packet dynamics it emerges that relaxation dominates the charge transfer. This behavior is reflected in transient absorption spectra, which are obtained from a directional decomposition of the time-dependent polarization. Due to the nature of the coupled dynamics the extraction of the relevant contributions needs an extension of well-known techniques for the decomposition.
Collapse
Affiliation(s)
- F Glaab
- Institut für Physikalische und Theoretische Chemie, Universität Würzburg, Emil-Fischer-Strasse 42, 97074 Würzburg, Germany
| | - C Lambert
- Institut für Organische Chemie, Universität Würzburg, Am Hubland, 97070 Würzburg, Germany
| | - V Engel
- Institut für Physikalische und Theoretische Chemie, Universität Würzburg, Emil-Fischer-Strasse 42, 97074 Würzburg, Germany
| |
Collapse
|
27
|
Guastella V, Piwko G, Greil A, Lambert C, Lautrette A. The opinion of French pulmonologists and palliative care physicians on non-invasive ventilation during palliative sedation at end of life: a nationwide survey. BMC Palliat Care 2021; 20:68. [PMID: 34001065 PMCID: PMC8130279 DOI: 10.1186/s12904-021-00755-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 03/15/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Deciding to withdraw non-invasive ventilation (NIV) at end-of-life (EOL) in patients with chronic respiratory failure is a challenge. The European Association for Palliative Care recommends not maintaining artificial therapies that could prolong life during palliative sedation (PS) at EOL. The aim of this survey was to assess palliative care physicians' and pulmonologists' opinion on withdrawing or maintaining NIV in patients with chronic respiratory failure during PS at EOL. METHODS From April to May 2019, we performed a prospective survey among pulmonologists (n = 1545) and palliative care physicians (n = 631) in France to determine the prevalence of opinion in favour of maintaining NIV and identify the factors associated with opinion in favour of withdrawing or maintaining NIV with multiple logistic regression. RESULTS A total of 457 participants were enrolled comprising 202 pulmonologists and 255 palliative care physicians. An opinion in favour of maintaining NIV was found in 88 (19.3 95%CI [15.7; 23.2]) physicians comprising 57 (28.2%) pulmonologists and 31 (12.2%) palliative care physicians (p < 0.001). The factors associated with an opinion in favour of maintaining NIV were spending time looking for advanced directives (AD) in the patient's file (odds ratio (OR): 6.54, 95%CI [2.00; 21.32], p = 0.002) and personal ethics of physicians (OR: 17.97, 95%CI [9.52; 33.89], p < 0.001). The factor associated with an opinion in favour of withdrawing NIV was palliative care training (OR: 0.31, 95%CI [0.16; 0.60], p < 0.001). The three main reasons in favour of maintaining NIV among the nine identified were emotional comfort for close relatives, reducing discomfort of dyspneoa and anticipation of suffocation. CONCLUSION In France, around 20% of pulmonologists and palliative care physicians declared an opinion in favour of maintaining NIV during PS at EOL because of their personal ethics and spending time looking for AD, if any, in the patient's file. Palliative care training can stimulate reflection help foster a change of opinion about practices, especially in the case of patients with NIV during PS at EOL.
Collapse
Affiliation(s)
- V. Guastella
- grid.411163.00000 0004 0639 4151Palliative Care Unit, Montpied Hospital, University Hospital of Clermont-Ferrand, 54 rue Montalembert, BP69, 63003 Clermont-Ferrand, Cedex 1, France
| | - G. Piwko
- grid.411163.00000 0004 0639 4151Pulmonology Unit, Montpied Hospital, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | - A. Greil
- grid.411163.00000 0004 0639 4151Pulmonology Unit, Montpied Hospital, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | - C. Lambert
- grid.411163.00000 0004 0639 4151Biostatistics unit (DRCI), Montpied Hospital, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | - A. Lautrette
- grid.411163.00000 0004 0639 4151Medical Intensive Care, Montpied Hospital, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| |
Collapse
|
28
|
Hickey S, Roe Y, Ireland S, Kildea S, Haora P, Gao Y, Maypilama EL, Kruske S, Campbell S, Moore S, Maidment SJ, Heinemann K, Hartz D, Adcock A, Storey F, Bennett M, Lambert C, Sibanda N, Lawton B, Cram F, Stevenson K, Lavoie J, Edmonds L, Geller S, Bourrassa C, Smylie J, Van Wagner V, Bourgeois C, Dion Fletcher C, King A, Briggs M, Worner F, Wellington C, Carson A, Nelson C, Watego K, Brown-Lolohea K, Colman K, Currie J, Lowell A, West R, Chamberlain C, Geia L, Sherwood J. A call for action that cannot go to voicemail: Research activism to urgently improve Indigenous perinatal health and wellbeing. Women Birth 2021; 34:303-305. [PMID: 33935005 DOI: 10.1016/j.wombi.2021.03.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Accepted: 03/28/2021] [Indexed: 11/19/2022]
Abstract
In this call to action, a coalition of Indigenous and non-Indigenous researchers from Australia, Aotearoa New Zealand, United States and Canada argue for the urgent need for adequately funded Indigenous-led solutions to perinatal health inequities for Indigenous families in well-resourced settler-colonial countries. Authors describe examples of successful community-driven programs making a difference and call on all peoples to support and resource Indigenous-led perinatal health services by providing practical actions for individuals and different groups.
Collapse
Affiliation(s)
- Sophie Hickey
- Molly Wardaguga Research Centre, Charles Darwin University, Australia.
| | - Yvette Roe
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Sarah Ireland
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Sue Kildea
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Penny Haora
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Yu Gao
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | | | - Sue Kruske
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Sandy Campbell
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Suzanne Moore
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | | | - Kayla Heinemann
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Donna Hartz
- Molly Wardaguga Research Centre, Charles Darwin University, Australia
| | - Anna Adcock
- Te Tātai Hauora O Hine - Centre for Women's Health Research, Te Wāhanga Tātai Hauora-Wellington Faculty of Health, Te Herenga Waka-Victoria University of Wellington, Aotearoa New Zealand
| | - Francesca Storey
- Te Tātai Hauora O Hine - Centre for Women's Health Research, Te Wāhanga Tātai Hauora-Wellington Faculty of Health, Te Herenga Waka-Victoria University of Wellington, Aotearoa New Zealand
| | - Matthew Bennett
- Te Tātai Hauora O Hine - Centre for Women's Health Research, Te Wāhanga Tātai Hauora-Wellington Faculty of Health, Te Herenga Waka-Victoria University of Wellington, Aotearoa New Zealand
| | - Charles Lambert
- Te Tātai Hauora O Hine - Centre for Women's Health Research, Te Wāhanga Tātai Hauora-Wellington Faculty of Health, Te Herenga Waka-Victoria University of Wellington, Aotearoa New Zealand
| | - Nokuthaba Sibanda
- Te Tātai Hauora O Hine - Centre for Women's Health Research, Te Wāhanga Tātai Hauora-Wellington Faculty of Health, Te Herenga Waka-Victoria University of Wellington, Aotearoa New Zealand
| | - Beverley Lawton
- Te Tātai Hauora O Hine - Centre for Women's Health Research, Te Wāhanga Tātai Hauora-Wellington Faculty of Health, Te Herenga Waka-Victoria University of Wellington, Aotearoa New Zealand
| | | | | | - Josée Lavoie
- Faculty of Health Sciences, University of Manitoba, Canada
| | - Liza Edmonds
- Southern District Health Board, Aotearoa New Zealand; Otago Medical School, University of Otago, Aotearoa New Zealand
| | - Stacie Geller
- Center for Research on Women & Gender, Department of Obstetrics & Gynecology, University of Illinois, United States
| | | | - Janet Smylie
- Well Living House Action Research Centre for Indigenous Infant, Child and Family Health and Wellbeing, St. Michael's Hospital, Dalla Lana School of Public Health, University of Toronto, Canada
| | | | - Cheryllee Bourgeois
- School of Midwifery, Ryerson University, Canada; Seventh Generation Midwives Toronto, Canada
| | - Claire Dion Fletcher
- School of Midwifery, Ryerson University, Canada; Seventh Generation Midwives Toronto, Canada
| | | | - Melanie Briggs
- Waminda South Coast Women's Health and Welfare Aboriginal Corporation, Australia
| | - Faye Worner
- Waminda South Coast Women's Health and Welfare Aboriginal Corporation, Australia
| | - Cleone Wellington
- Waminda South Coast Women's Health and Welfare Aboriginal Corporation, Australia
| | | | | | | | | | - Kady Colman
- Institute for Urban Indigenous Health, Australia
| | - Jody Currie
- Aboriginal and Torres Strait Islander Community Health Service Brisbane Limited, Australia
| | - Anne Lowell
- Northern Institute, Charles Darwin University, Australia
| | - Roianne West
- Congress of Aboriginal and Torres Strait Islander Nurses and Midwives, Australia
| | | | | | | |
Collapse
|
29
|
Chambonniere C, Lambert C, Tardieu M, Fillon A, Genin P, Larras B, Melsens P, Baker JS, Pereira B, Tremblay A, Thivel D, Duclos M. Physical Activity and Sedentary Behavior of Elderly Populations during Confinement: Results from the FRENCH COVID-19 ONAPS Survey. Exp Aging Res 2021; 47:401-413. [PMID: 33827390 DOI: 10.1080/0361073x.2021.1908750] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Introduction: A national confinement was imposed in France in March 2020 during 55 days to prevent the spread of the virus and protect vulnerable people such as older individuals. This study aimed to describe the movement behaviors, and their determinants, of elderly people (≥ 65 years) during the confinement.Methods: An online survey was conducted from April 1st, 2020 to May 6th, 2020 by the National Observatory for Physical Activity and Sedentary behaviors. This study compared the level of physical activity (PA), sitting and screen time before and during the confinement and identified the impact of initial PA, sedentary profiles of the participants and housing conditions.Results: 1,178 people were included in this study. Reaching PA recommendations before lock-down was associated with the change in PA level during lock-down (p < .001). Besides, geographic location was associated with the change in PA, sitting time and screen time during lock-down (respectively p = .03, p = .02, p = .02).Conclusion: This study confirm the negative impact of confinement on senior movement behaviors, whether or not they met with public health recommendations prior to the pandemic. The housing conditions of older people must be also taken into future public health policies.
Collapse
Affiliation(s)
- C Chambonniere
- Clermont Auvergne University, EA 3533, Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), CRNH Auvergne, Clermont-Ferrand, France.,Inrae, Umr Clermont-Ferrand, France
| | - C Lambert
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France.,Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI), Clermont-Ferrand, France
| | - M Tardieu
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France
| | - A Fillon
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France
| | - P Genin
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France
| | - B Larras
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France
| | - P Melsens
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France
| | - J S Baker
- Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong
| | - B Pereira
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France.,Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI), Clermont-Ferrand, France
| | - A Tremblay
- National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France.,Department of Kinesiology, Faculty of Medicine, University of Laval, Quebec City. Canada
| | - D Thivel
- Clermont Auvergne University, EA 3533, Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), CRNH Auvergne, Clermont-Ferrand, France.,National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France
| | - M Duclos
- Inrae, Umr Clermont-Ferrand, France.,National Observatory for Physical Activity and Sedentary Behaviors (ONAPS), Clermont-Ferrand, France.,University Clermont 1, UFR Medicine, Clermont-Ferrand, France.,Department of Sport Medicine and Functional Explorations, Clermont-Ferrand University Hospital, G. Montpied Hospital, Clermont-Ferrand, France
| |
Collapse
|
30
|
Harding AT, Weeks BK, Lambert C, Watson SL, Weis LJ, Beck BR. Exploring thoracic kyphosis and incident fracture from vertebral morphology with high-intensity exercise in middle-aged and older men with osteopenia and osteoporosis: a secondary analysis of the LIFTMOR-M trial. Osteoporos Int 2021; 32:451-465. [PMID: 32935171 DOI: 10.1007/s00198-020-05583-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Accepted: 08/03/2020] [Indexed: 11/28/2022]
Abstract
UNLABELLED Our aim was to explore change in kyphosis and vertebral fracture incidence following 8 months of high-intensity resistance and impact training (HiRIT) or machine-based isometric axial compression (IAC) training in men with osteopenia and osteoporosis. HiRIT and IAC improved posture. HiRIT participants did not experience progression or incident vertebral fracture. IAC participants did experience progression and incident vertebral fracture. INTRODUCTION The Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation for Men (LIFTMOR-M) trial examined efficacy and safety of an eight-month, supervised, high-intensity progressive resistance and impact training (HiRIT) program compared with machine-based isometric axial compression (IAC) training in middle-aged and older men with low areal bone mineral density (aBMD). The primary purpose of the current work was to explore change in thoracic kyphosis and incident fracture from vertebral morphology following eight-months of HiRIT or IAC training. The secondary purpose was to explore change in clinical kyphosis measures for HiRIT, IAC and a non-randomized, matched control group. METHODS Men (≥ 45 yrs), with low aBMD, were recruited and randomized to HiRIT or IAC, or designated control. Clinical measures of thoracic kyphosis with inclinometry were determined. Cobb angle of kyphosis and vertebral fracture assessment using the Genant semi-quantitative method were determined from lateral thoracolumbar DXA (Medix DR, Medilink, France). Per-protocol (n = 40) and intention-to-treat (n = 93) analyses were conducted. RESULTS Forty participants (HiRIT n = 20, IAC n = 20; 66.1 ± 7.8 yrs.; lumbar spine T-score - 0.1 ± 0.8; femoral neck T-score - 1.5 ± 0.5) underwent clinical kyphosis measures and thoracolumbar DXA at baseline and follow-up. No between-group differences were detected in kyphosis change, however, within-group improvements in neutral (HiRIT - 2.3 ± 0.8°; IAC - 2.5 ± 0.8°) and 'standing tall' (HiRIT - 2.4 ± 0.8°; IAC - 2.0 ± 0.8°) postures were observed (p < 0.05). HiRIT improved Cobb angle (- 3.5 ± 1.5°, p = 0.027) from baseline. Over the 8 months, no incident vertebral fractures nor progression of prevalent vertebral fractures occurred for HiRIT participants. Five incident fractures of thoracic vertebrae occurred for IAC and one wedge fracture progressed. Ninety-three participants underwent clinical kyphosis measures at both time-points (HiRIT n = 34, IAC n = 33, control n = 26). HiRIT exhibited a reduction in 'standing tall' kyphosis compared to control (- 2.3 ± 0.6° versus 1.4 ± 0.7°, p < 0.05), but no other between-group differences were detected. CONCLUSIONS Although there was no difference in change between intervention groups, thoracic kyphosis appeared to improve in both HiRIT and IAC with exercise exposure. HiRIT improved 'standing tall' posture in comparison to usual activities. HiRIT was not associated with vertebral fracture progression or incident vertebral fracture, but for some IAC participants there was evidence of progression of vertebral fracture severity and incident vertebral fractures, in our small sample. Larger trials are required to confirm the observations of the current work, which was exploratory in nature.
Collapse
Affiliation(s)
- A T Harding
- Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
- School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, 4222, Australia
| | - B K Weeks
- Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
- School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, 4222, Australia
| | - C Lambert
- Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
- School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, 4222, Australia
| | - S L Watson
- Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
- School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, 4222, Australia
| | - L J Weis
- The Bone Clinic, Brisbane, Queensland, Australia
| | - B R Beck
- Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia.
- School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, 4222, Australia.
- The Bone Clinic, Brisbane, Queensland, Australia.
| |
Collapse
|
31
|
Bornstein SR, Guan K, Brunßen C, Mueller G, Kamvissi-Lorenz V, Lechler R, Trembath R, Mayr M, Poston L, Sancho R, Ahmed S, Alfar E, Aljani B, Alves TC, Amiel S, Andoniadou CL, Bandral M, Belavgeni A, Berger I, Birkenfeld A, Bonifacio E, Chavakis T, Chawla P, Choudhary P, Cujba AM, Delgadillo Silva LF, Demcollari T, Drotar DM, Duin S, El-Agroudy NN, El-Armouche A, Eugster A, Gado M, Gavalas A, Gelinsky M, Guirgus M, Hansen S, Hanton E, Hasse M, Henneicke H, Heller C, Hempel H, Hogstrand C, Hopkins D, Jarc L, Jones PM, Kamel M, Kämmerer S, King AJF, Kurzbach A, Lambert C, Latunde-Dada Y, Lieberam I, Liers J, Li JW, Linkermann A, Locke S, Ludwig B, Manea T, Maremonti F, Marinicova Z, McGowan BM, Mickunas M, Mingrone G, Mohanraj K, Morawietz H, Ninov N, Peakman M, Persaud SJ, Pietzsch J, Cachorro E, Pullen TJ, Pyrina I, Rubino F, Santambrogio A, Schepp F, Schlinkert P, Scriba LD, Siow R, Solimena M, Spagnoli FM, Speier S, Stavridou A, Steenblock C, Strano A, Taylor P, Tiepner A, Tonnus W, Tree T, Watt F, Werdermann M, Wilson M, Yusuf N, Ziegler CG. The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease. Horm Metab Res 2021; 53:204-206. [PMID: 33652492 DOI: 10.1055/a-1377-6583] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Currently, we are experiencing a true pandemic of a communicable disease by the virus SARS-CoV-2 holding the whole world firmly in its grasp. Amazingly and unfortunately, this virus uses a metabolic and endocrine pathway via ACE2 to enter our cells causing damage and disease. Our international research training programme funded by the German Research Foundation has a clear mission to train the best students wherever they may come from to learn to tackle the enormous challenges of diabetes and its complications for our society. A modern training programme in diabetes and metabolism does not only involve a thorough understanding of classical physiology, biology and clinical diabetology but has to bring together an interdisciplinary team. With the arrival of the coronavirus pandemic, this prestigious and unique metabolic training programme is facing new challenges but also new opportunities. The consortium of the training programme has recognized early on the need for a guidance and for practical recommendations to cope with the COVID-19 pandemic for the community of patients with metabolic disease, obesity and diabetes. This involves the optimal management from surgical obesity programmes to medications and insulin replacement. We also established a global registry analyzing the dimension and role of metabolic disease including new onset diabetes potentially triggered by the virus. We have involved experts of infectious disease and virology to our faculty with this metabolic training programme to offer the full breadth and scope of expertise needed to meet these scientific challenges. We have all learned that this pandemic does not respect or heed any national borders and that we have to work together as a global community. We believe that this transCampus metabolic training programme provides a prime example how an international team of established experts in the field of metabolism can work together with students from all over the world to address a new pandemic.
Collapse
Affiliation(s)
- S R Bornstein
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- University Hospital Zurich, Department of Endocrinology and Diabetology, Zurich, Switzerland
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - K Guan
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - C Brunßen
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - G Mueller
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - V Kamvissi-Lorenz
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | | | - R Trembath
- Department of Medical & Molecular Genetics, King's College London, London, UK
| | - M Mayr
- School of Cardiovascular Medicine and Science, Faculty of Life Science & Medicine, KCL, London, UK
| | - L Poston
- Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK
| | - R Sancho
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - S Ahmed
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - E Alfar
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - B Aljani
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - T C Alves
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - S Amiel
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - C L Andoniadou
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Craniofacial Development and Stem Cell Biology, KCL, London, UK
| | - M Bandral
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - A Belavgeni
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - I Berger
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A Birkenfeld
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
| | - E Bonifacio
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - T Chavakis
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - P Chawla
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - P Choudhary
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A M Cujba
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - L F Delgadillo Silva
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - T Demcollari
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - D M Drotar
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - S Duin
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Centre for Translational Bone, Joint and Soft Tissue Research, Medical Faculty and University Hospital, Technische Universität Dresden, Dresden, Germany
| | - N N El-Agroudy
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A El-Armouche
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - A Eugster
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - M Gado
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A Gavalas
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - M Gelinsky
- Centre for Translational Bone, Joint and Soft Tissue Research, Medical Faculty and University Hospital, Technische Universität Dresden, Dresden, Germany
| | - M Guirgus
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - S Hansen
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - E Hanton
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - M Hasse
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - H Henneicke
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - C Heller
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - H Hempel
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - C Hogstrand
- Department of Nutritional Sciences, Faculty of Life Sciences & Medicine, KCL, London, UK
| | - D Hopkins
- Department of Diabetic Medicine, King's College Hospital NHS Foundation Trust and KCL, London, UK
| | - L Jarc
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - P M Jones
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - M Kamel
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - S Kämmerer
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - A J F King
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A Kurzbach
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - C Lambert
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | | | - I Lieberam
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - J Liers
- Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - J W Li
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - A Linkermann
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - S Locke
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - B Ludwig
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- University Hospital Zurich, Department of Endocrinology and Diabetology, Zurich, Switzerland
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - T Manea
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - F Maremonti
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - Z Marinicova
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - B M McGowan
- Department of Diabetes and Endocrinology, London, UK
| | - M Mickunas
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - G Mingrone
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- Università Cattolica del Sacro Cuore, Rome, Italy
| | - K Mohanraj
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - H Morawietz
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - N Ninov
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - M Peakman
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - S J Persaud
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - J Pietzsch
- Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - E Cachorro
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - T J Pullen
- School of Life Course Sciences, Faculty of Life Sciences & Medicine, KCL, London, UK
| | - I Pyrina
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - F Rubino
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A Santambrogio
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - F Schepp
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - P Schlinkert
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - L D Scriba
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - R Siow
- Vascular Biology & Inflammation Section, School of Cardiovascular Medicine & Sciences, British Heart Foundation of Research Excellence, King's College London, London, UK
| | - M Solimena
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
- Molecular Diabetology, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - F M Spagnoli
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - S Speier
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - A Stavridou
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - C Steenblock
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A Strano
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - P Taylor
- Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK
| | - A Tiepner
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - W Tonnus
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - T Tree
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - F Watt
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - M Werdermann
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - M Wilson
- School of Life Course Sciences, Faculty of Life Sciences & Medicine, KCL, London, UK
| | - N Yusuf
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - C G Ziegler
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| |
Collapse
|
32
|
Tallec K, Paul-Pont I, Petton B, Alunno-Bruscia M, Bourdon C, Bernardini I, Boulais M, Lambert C, Quéré C, Bideau A, Le Goïc N, Cassone AL, Le Grand F, Fabioux C, Soudant P, Huvet A. Amino-nanopolystyrene exposures of oyster ( Crassostrea gigas) embryos induced no apparent intergenerational effects. Nanotoxicology 2021; 15:477-493. [PMID: 33555961 DOI: 10.1080/17435390.2021.1879963] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Early life stages (ELS) of numerous marine invertebrates mustcope with man-made contaminants, including plastic debris, during their pelagic phase. Among the diversity of plastic particles, nano-sized debris, known as nanoplastics, can induce effects with severe outcomes in ELS of various biological models, including the Pacific oyster Crassostrea gigas. Here, we investigated the effects of a sub-lethal dose (0.1 µg mL-1) of 50 nm polystyrene nanobeads (nano-PS) with amine functions on oyster embryos (24 h exposure) and we assessed consequences on larval and adult performances over two generations of oysters. Only a few effects were observed. Lipid analyses revealed that first-generation (G1) embryos exposed to nano-PS displayed a relative increase in cardiolipin content (+9.7%), suggesting a potential modification of mitochondrial functioning. G1-larvae issued from exposed embryos showed decreases in larval growth (-9%) and lipid storage (-20%). No effect was observed at the G1 adult stage in terms of growth, ecophysiological parameters (clearance and respiration rates, absorption efficiency), or reproductive outputs (gonadic development, gamete quality). Second generation (G2) larvae issued from control G1 displayed a significant growth reduction after G2 embryonic exposure to nano-PS (-24%) compared to control (as observed at the first generation), while no intergenerational effect was detected on G2 larvae issued from G1 exposed embryos. Overall, the present experimental study suggests a low incidence of a short embryonic exposure to nano-PS on oyster phenotypes along the entire life cycle until the next larval generation.
Collapse
Affiliation(s)
- K Tallec
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - I Paul-Pont
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - B Petton
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - M Alunno-Bruscia
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - C Bourdon
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - I Bernardini
- Dipartimento di Biomedicina Comparata e Alimentazione, Università degli Studi di Padova, Padova, Italy.,Department of Physical, Earth and Environmental Sciences, University of Siena, Siena, Italy
| | - M Boulais
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - C Lambert
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - C Quéré
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - A Bideau
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - N Le Goïc
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - A-L Cassone
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - F Le Grand
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - C Fabioux
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - P Soudant
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| | - A Huvet
- University of Brest, Ifremer, CNRS, IRD, LEMAR, F-29280, Plouzané, France
| |
Collapse
|
33
|
Lawton B, Storey F, Sibanda N, Bennett M, Lambert C, Geller S, Edmonds L, Cram F. He Korowai Manaaki (Pregnancy Wraparound Care): Protocol for a Cluster Randomized Clinical Trial. JMIR Res Protoc 2021; 10:e18154. [PMID: 33512321 PMCID: PMC7880808 DOI: 10.2196/18154] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Revised: 10/01/2020] [Accepted: 12/15/2020] [Indexed: 11/22/2022] Open
Abstract
Background Maternal and infant health inequities between Māori (the Indigenous peoples of Aotearoa New Zealand) and New Zealand European women are well documented and cannot be explained solely by socioeconomic status. A research center-iwi (tribal group) partnership aims to address these disparities and improve maternal and infant health outcomes by implementing an augmented maternity care pathway (He Korowai Manaaki) to improve access to services and evidence-informed care. Objective The objective of this study is to test whether an augmented maternity care pathway improves Māori infant health outcomes. Methods This is a Kaupapa Māori (by, with, and for Māori) cluster randomized clinical trial involving 8 primary care practices allocated to either an intervention arm or control arm. The intervention arm comprises an augmented maternity care pathway (He Korowai Manaaki) offering clinical care through additional paid health care appointments and improved access to social support (eg, housing, transport). The control arm is usual care. The primary outcome is increased timely vaccination for Māori infants, defined as all age-appropriate vaccinations completed by 6 months of age. Results Recruitment commenced in November 2018 and was completed in June 2020, with 251 enrolled women recruited in intervention primary care practices before 20 weeks of pregnancy. Publication of results is anticipated in late 2023. Conclusions The results will inform primary health care policy including whether the provision of augmented maternal care pathways reduces disparities in the structural determinants of health. If effective, He Korowai Manaaki will strengthen the health and well-being of pregnant Māori women and their babies and improve their health outcomes, laying a strong foundation for lifelong health and well-being. Trial Registration Australian New Zealand Clinical Trials Registry ACTRN12619001155189; https://tinyurl.com/yypbef8q International Registered Report Identifier (IRRID) DERR1-10.2196/18154
Collapse
Affiliation(s)
- Beverley Lawton
- Centre for Women's Health Research, Victoria University of Wellington, Wellington, New Zealand
| | - Francesca Storey
- Centre for Women's Health Research, Victoria University of Wellington, Wellington, New Zealand
| | - Nokuthaba Sibanda
- Centre for Women's Health Research, Victoria University of Wellington, Wellington, New Zealand
| | - Matthew Bennett
- Centre for Women's Health Research, Victoria University of Wellington, Wellington, New Zealand
| | - Charles Lambert
- Centre for Women's Health Research, Victoria University of Wellington, Wellington, New Zealand
| | - Stacie Geller
- Center for Research on Women & Gender, Center of Excellence in Women's Health, Department of Obstetrics and Gynaecology, University of Illinois, Chicago, IL, United States
| | - Liza Edmonds
- Women's & Children's Health, University of Otago, Dunedin, New Zealand
| | | |
Collapse
|
34
|
Heshmatpour C, Malevich P, Plasser F, Menger M, Lambert C, Šanda F, Hauer J. Annihilation Dynamics of Molecular Excitons Measured at a Single Perturbative Excitation Energy. J Phys Chem Lett 2020; 11:7776-7781. [PMID: 32842744 DOI: 10.1021/acs.jpclett.0c02141] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Exciton-exciton annihilation (EEA) is a ubiquitous phenomenon, which may limit the efficiency of photovoltaic devices. Conventional methods of determining EEA time scales rely on measuring the intensity dependence of third-order signals. In this work, we directly extract the annihilation rate of molecular excitons in a covalently joined molecular trimer without the need to perform and analyze intensity dependent data by employing fifth-order coherent optical spectroscopy signals emitted into ±2k⃗1 ∓ 2k⃗2 + k⃗3 phase matching directions. Measured two-dimensional line shapes and their time traces are analyzed in the framework of the many-body version of the Frenkel exciton model, extended to incorporate annihilation dynamics. Combining double-sided Feynman diagrams with explicit simulations of the fifth-order response, we identify a single peak as a direct reporter of EEA. We retrieve an annihilation time of 30 fs for the investigated squaraine trimer.
Collapse
Affiliation(s)
- C Heshmatpour
- Institute of Physics, Faculty of Mathematics and Physics, Charles University, Ke Karlovu 5, Prague 121 16, Czech Republic
- Professur für Dynamische Spektroskopien, Fakultät für Chemie, Technische Universität München, Lichtenbergstrasse 4, D-85748, Garching b. München, Germany
| | - P Malevich
- Professur für Dynamische Spektroskopien, Fakultät für Chemie, Technische Universität München, Lichtenbergstrasse 4, D-85748, Garching b. München, Germany
| | - F Plasser
- Department of Chemistry, Loughborough University, Loughborough LE11 3TU, United Kingdom
| | - M Menger
- Faculty of Science and Engineering, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747AG Groningen, The Netherlands
| | - C Lambert
- Institut für Organische Chemie, Center for Nanosystems Chemistry, Universität Würzburg, Am Hubland, 97074 Würzburg, Germany
| | - F Šanda
- Institute of Physics, Faculty of Mathematics and Physics, Charles University, Ke Karlovu 5, Prague 121 16, Czech Republic
| | - J Hauer
- Professur für Dynamische Spektroskopien, Fakultät für Chemie, Technische Universität München, Lichtenbergstrasse 4, D-85748, Garching b. München, Germany
| |
Collapse
|
35
|
Puechmaille M, Lambert C, Aubry K, Bordure P, Bozorg-Grayeli A, Deguine O, Eyermann C, Franco-Vidal V, Godey B, Guevara N, Karkas A, Klopp N, Labrousse M, Lebreton JP, Lerosey Y, Lescanne E, Loundon N, Marianowski R, Merklen F, Mezouaghi K, Moreau S, Mosnier I, Noël-Petroff N, Parietti-Winkler C, Piller P, Poncet C, Radafy E, Roman S, Roux-Vaillard S, Schmerber S, Tavernier L, Truy E, Vincent C, Mom T. The French National Cochlear Implant Registry (EPIIC): Bilateral cochlear implantation. Eur Ann Otorhinolaryngol Head Neck Dis 2020; 137 Suppl 1:S51-S56. [DOI: 10.1016/j.anorl.2020.07.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Tallec K, Paul-Pont I, Boulais M, Le Goïc N, González-Fernández C, Le Grand F, Bideau A, Quéré C, Cassone AL, Lambert C, Soudant P, Huvet A. Nanopolystyrene beads affect motility and reproductive success of oyster spermatozoa ( Crassostrea gigas). Nanotoxicology 2020; 14:1039-1057. [PMID: 32813582 DOI: 10.1080/17435390.2020.1808104] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Oysters are keystone species that use external fertilization as a sexual mode. The gametes are planktonic and face a wide range of stressors, including plastic litter. Nanoplastics are of increasing concern because their size allows pronounced interactions with biological membranes, making them a potential hazard to marine life. In the present study, oyster spermatozoa were exposed for 1 h to various doses (from 0.1 to 25 µg mL-1) of 50-nm polystyrene beads with amine (50-NH2 beads) or carboxyl (50-COOH beads) functions. Microscopy revealed adhesion of particles to the spermatozoa membranes, but no translocation of either particle type into cells. Nevertheless, the 50-NH2 beads at 10 µg mL-1 induced a high spermiotoxicity, characterized by a decrease in the percentage of motile spermatozoa (-79%) and in the velocity (-62%) compared to control spermatozoa, with an overall drop in embryogenesis success (-59%). This major reproduction failure could be linked to a homeostasis disruption in exposed spermatozoa. The 50-COOH beads hampered spermatozoa motility only when administered at 25 µg mL-1 and caused a decrease in the percentage of motile spermatozoa (-66%) and in the velocity (-38%), but did not affect embryogenesis success. Microscopy analyses indicated these effects were probably due to physical blockages by microscale aggregates formed by the 50-COOH beads in seawater. This toxicological study emphasizes that oyster spermatozoa are a useful and sensitive model for (i) deciphering the fine interactions underpinning nanoplastic toxicity and (ii) evaluating adverse effects of plastic nanoparticles on marine biota while waiting for their concentration to be known in the environment.
Collapse
Affiliation(s)
- K Tallec
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - I Paul-Pont
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - M Boulais
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - N Le Goïc
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | | | - F Le Grand
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - A Bideau
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - C Quéré
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - A-L Cassone
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - C Lambert
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - P Soudant
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| | - A Huvet
- Univ Brest, Ifremer, CNRS, IRD, LEMAR, Plouzané, France
| |
Collapse
|
37
|
D'Incan M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, Grange F, Quereux G, Templier I, Ram-Wolff C, Adamski H, Lambert C, Descours C. Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. Br J Dermatol 2020; 184:356-358. [PMID: 32810288 DOI: 10.1111/bjd.19495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 07/30/2020] [Accepted: 08/14/2020] [Indexed: 11/28/2022]
Affiliation(s)
- M D'Incan
- Department of Dermatology and Skin Oncology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - M Beylot-Barry
- Department of Dermatology, CHU de Bordeaux, Bordeaux, France
| | - P Joly
- Department of Dermatology, CHU de Rouen, Rouen, France
| | - F Grange
- Department of Dermatology, CHU de Reims, Reims, France
| | - G Quereux
- Department of Dermatology, CHU de Nantes, Nantes, France
| | - I Templier
- Department of Dermatology, CHU de Grenoble, Grenoble, France
| | - C Ram-Wolff
- Department of Dermatology, Hôpital Saint-Louis, Paris, France
| | - H Adamski
- Department of Dermatology, CHU de Rennes, Rennes, France
| | - C Lambert
- Department of Biostatistics, CHU de Clermont-Ferrand, France
| | - C Descours
- Department of Dermatology and Skin Oncology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| |
Collapse
|
38
|
Lambert C, Authier M, Dorémus G, Laran S, Panigada S, Spitz J, Van Canneyt O, Ridoux V. Setting the scene for Mediterranean litterscape management: The first basin-scale quantification and mapping of floating marine debris. Environ Pollut 2020; 263:114430. [PMID: 32311635 DOI: 10.1016/j.envpol.2020.114430] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 03/17/2020] [Accepted: 03/19/2020] [Indexed: 06/11/2023]
Abstract
Plastic pollution has become one of the biggest environmental concerns of the Anthropocene as it represents a major threat to both wildlife and human health. Garbage patches in the world's oceans are well documented, but quantitative assessments of floating debris are still lacking in some major areas. The Mediterranean Sea is one such area, despite being one of the most plastic polluted environments. We used data from the first international basin-scale survey of the Mediterranean Sea to provide the first abundance estimate of floating mega-debris (>30 cm) and map their distribution over the entire Mediterranean Sea. We estimated the total number of floating mega-debris at 2.9 million items, taking into account imperfect detection. Items larger than 30 cm represent only one fourth of the complete load of anthropogenic debris (>2 cm) in the Mediterranean, which scales up the estimate to 11.5 million floating debris. The highest densities were observed in the central Mediterranean, and the lowest in the eastern basin. This acute marine pollution might threaten to disrupt entire ecosystems through its impact on marine fauna (entanglement, ingestion, contamination), eventually impacting the tourism industry and the well-being of Mediterranean populations.
Collapse
Affiliation(s)
- C Lambert
- Observatoire Pelagis, UMS 3462 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France.
| | - M Authier
- Observatoire Pelagis, UMS 3462 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France; ADERA, 162 Avenue Albert Schweitzer CS 60040, 33608, Pessac, Cedex, France
| | - G Dorémus
- Observatoire Pelagis, UMS 3462 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France
| | - S Laran
- Observatoire Pelagis, UMS 3462 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France; ADERA, 162 Avenue Albert Schweitzer CS 60040, 33608, Pessac, Cedex, France
| | - S Panigada
- Tethys Research Institute, Viale G.B. Gadio 2, 20121, Milano, Italy; ACCOBAMS, Jardin de l'UNESCO, Terrasses de Fontvieille, 98000, Monaco
| | - J Spitz
- Observatoire Pelagis, UMS 3462 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France; Centre d' Études Biologiques de Chizé, UMR 7372 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France
| | - O Van Canneyt
- Observatoire Pelagis, UMS 3462 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France
| | - V Ridoux
- Observatoire Pelagis, UMS 3462 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France; Centre d' Études Biologiques de Chizé, UMR 7372 CNRS - La Rochelle Université, 5 Allées de l'Océan, 17000, La Rochelle, France
| |
Collapse
|
39
|
Jacomet C, Linard F, Prouteau J, Lambert C, Ologeanu-Taddei R, Bastiani P, Dellamonica P. E-health. Patterns of use and perceived benefits and barriers among people living with HIV (PLHIV) and their physicians - Part 3: Telemedicine and collection of computerized personal information. Med Mal Infect 2020; 50:590-596. [PMID: 32320726 DOI: 10.1016/j.medmal.2020.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 12/01/2019] [Accepted: 04/09/2020] [Indexed: 10/24/2022]
Abstract
OBJECTIVES To evaluate the patterns of use and perceived benefits and barriers among people living with HIV and their physicians concerning telemedicine and the collection of computerized personal information. METHODS Multicenter online observational survey from October 15 to 19, 2018. RESULTS Study participation was accepted by 229 physicians and 838/1,377 PLHIV followed in 46 centers, of which 325 (39%) responded online. We found that while 226/302 (75%) PLHIV accept online prescription renewals and 197/302 (65%) accept online medical certificates, 182/302 (60%) PLHIV-who were more often in material/social deprivation (OR=1.70±0.45; P=0.045), less often born in Île-de-France (OR=0.43±0.15; P=0.018), with lower CD4 T-cell counts (OR=0.999±0.0004; P=0.038), and less often on psychiatric treatment (OR=0.50±0.18; P=0.047)-were receptive to teleconsultations. However, 137/225 (61%) physicians would be uncomfortable teleconsulting due to inadequate data security without it reducing the number of consultations or offering economic benefit. Asked about collection of computerized personal information, 197/296 (67%) PLHIV and 139/223 (62%) physicians agreed it improved quality of care, but 144 (49%) PLHIV and 94/222 (42%) physicians thought it was not sufficiently framed by the law. eHealth was seen as improving coordination between health professionals by 240/296 (81%) PLHIV and seen as a good thing by 181/225 (81%) physicians. CONCLUSION More than half of PLHIV were ready for telemedicine. PLHIV and physicians endorsed the advantage of e-health in terms of better coordination across health professionals but mistrust the data collection factor, which warrants either clarification or stronger legal protections.
Collapse
Affiliation(s)
- C Jacomet
- Service des maladies infectieuses et tropicales, CHU de Clermont-Ferrand, France.
| | - F Linard
- Services des maladies infectieuses et tropicales, CHU de Tenon, CHU de Hôtel-Dieu, Sorbonne Université, AP-HP, France
| | - J Prouteau
- Service des maladies infectieuses et tropicales, CHU de Clermont-Ferrand, France
| | - C Lambert
- Délégation recherche clinique & innovation, CHU de Clermont-Ferrand, France
| | - R Ologeanu-Taddei
- Systèmes d'Information, Montpellier recherche en management & polytech Montpellier, université de Montpellier, France
| | | | - P Dellamonica
- Service des maladies infectieuses et tropicales, université de la Côte-d'Azur, France
| |
Collapse
|
40
|
Jacomet C, Ologeanu-Taddei R, Prouteau J, Lambert C, Linard F, Bastiani P, Dellamonica P. E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 2: Health apps and smart devices. Med Mal Infect 2020; 50:582-589. [PMID: 32302672 DOI: 10.1016/j.medmal.2020.04.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 12/01/2019] [Accepted: 04/07/2020] [Indexed: 12/25/2022]
Abstract
OBJECTIVES To evaluate patterns of use and perceived benefits and barriers to health/wellness applications (apps) and smart devices among people living with HIV (PLHIV) and their physicians. METHODS Online multicenter observational survey (October 15-19, 2018). RESULTS Study participation was accepted by 229 physicians and 838/1377 PLHIV followed in 46 centers, of which 325 (39%) responded online. Overall, 83/288 (29%) PLHIV had already downloaded at least one app: these 'downloaders' were younger (OR0.96±0.01, P=0.004), educated to at least university entry level (OR2.27±0.86, P=0.03), and more frequently used geolocation-based dating websites (OR3.00±1.09, P=0.002). However, 227/314 (72%) PLHIV claimed they were ready to use an app recommended by a physician. For the 60/83 PLHIV who answered, the ideal app would be a vaccination tracker (76%) to better communicate with their physician (68%). However, 96/277 (42%) physicians were unable to answer this question and for 94/227 (41%) of them, the ideal patient app would be for schedule management. Although PLHIV used smart devices, 231/306 (75%) would want to report the data to their physicians and 137/225 (61%) of physicians would welcome this exchange. The main physician-side barrier to this exchange was concerns over data security. CONCLUSION mHealth apps and smart devices have failed to garner adoption by PLHIV. There is a case for good-quality health data sharing and exchange if PLHIV are provided with appropriately secure tools and physicians are backed up by adapted legislation.
Collapse
Affiliation(s)
- C Jacomet
- Service des maladies infectieuses et tropicales, CHU de Clermont-Ferrand, Clermont ferrand, France.
| | - R Ologeanu-Taddei
- Systèmes d'information-Montpellier recherche en management & polytech Montpellier, Université de Montpellier, Montpellier, France
| | - J Prouteau
- Service des maladies infectieuses et tropicales, CHU de Clermont-Ferrand, Clermont ferrand, France
| | - C Lambert
- Délégation recherche clinique & innovation, CHU de Clermont-Ferrand, Clermont ferrand, France
| | - F Linard
- Services des maladies infectieuses et tropicales, CHU de Tenon, CHU de Hôtel-Dieu, Sorbonne Université, AP-HP, Paris, France
| | | | - P Dellamonica
- Service des maladies infectieuses et tropicales, Université de la Côte d'Azur, Nice, France
| |
Collapse
|
41
|
Moustafa F, Corriger A, Lambert C, Barres A, Camminada C, Teissandier D, Saint-Denis J, Dutheil F, Schmidt J. Management of major bleeding outcomes under antithrombotic therapy in real-life. Thromb Res 2020; 187:28-31. [DOI: 10.1016/j.thromres.2020.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 11/22/2019] [Accepted: 01/08/2020] [Indexed: 10/25/2022]
|
42
|
Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, Bourre B, Créange A, Kerschen P, Montcuquet A, Carra-Dalliere C, Ayrignac X, Labauge P, de Seze J, Collongues N. Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. Mult Scler 2020; 27:232-238. [DOI: 10.1177/1352458520906995] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Atypical myelitis in multiple sclerosis (MS) is characterized by extensive myelitis in the longitudinal (longitudinally extensive transverse myelitis) or axial plane (transverse myelitis). Objective: To characterize a cohort of MS patients with atypical myelitis. Methods: Atypical myelitis was extracted from the French and Luxembourg MS databases and compared to two cohorts of MS patients with typical myelitis and neuromyelitis optica spectrum disorders (NMOSDs) patients with myelitis. Results: We enrolled 28 MS patients with atypical myelitis, 68 MS patients with typical myelitis and 119 NMOSD patients with a first episode of myelitis. MS patients with atypical myelitis were characterized by a mean age of 34.0 (±10.7) years and 64.3% were women. In 82.1% of the patients, atypical myelitis was the first episode of MS. Mean Expanded Disability Status Scale (EDSS) scores at nadir and 3–6 months after onset were 4.1 ± 2.1 and 3.3 ± 2, respectively. Differences between groups revealed a predominance of cervicothoracic myelitis and a higher level of disability in NMOSD patients. Disability in MS patients with atypical myelitis was more severe than in the MS patients with typical myelitis; 28% had already converted to progressive MS within our mean follow-up of 39.6 (±30.4) months. Conclusion: Atypical myelitis may be the first presentation of MS and is associated with poorer prognosis.
Collapse
Affiliation(s)
- K Bigaut
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - C Lambert
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - L Kremer
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - C Lebrun
- CRC-SEP, Neurologie, Université Nice Côte d’Azur, CHU Pasteur 2, Nice, France
| | - M Cohen
- CRC-SEP, Neurologie, Université Nice Côte d’Azur, CHU Pasteur 2, Nice, France
| | - J Ciron
- CRC-SEP, Neurologie, CHU Toulouse, Toulouse, France
| | - B Bourre
- Service de Neurologie, CHU de Rouen, Rouen, France
| | - A Créange
- Service de Neurologie, CHU de Créteil, Paris, France
| | - P Kerschen
- Service de Neurologie, Centre Hospitalier de Luxembourg, Luxembourg
| | - A Montcuquet
- Service de Neurologie, CHU de Limoges, Limoges, France
| | | | - X Ayrignac
- CRC-SEP, Neurologie, CHU de Montpellier, Montpellier, France
| | - P Labauge
- CRC-SEP, Neurologie, CHU de Montpellier, Montpellier, France
| | - J de Seze
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - N Collongues
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| |
Collapse
|
43
|
Wittstein K, Cordsmeier A, Lambert C, Wendt L, Sir EB, Weber J, Wurzler N, Petrini LE, Stadler M. Identification of Rosellinia species as producers of cyclodepsipeptide PF1022 A and resurrection of the genus Dematophora as inferred from polythetic taxonomy. Stud Mycol 2020; 96:1-16. [PMID: 32165986 PMCID: PMC7056724 DOI: 10.1016/j.simyco.2020.01.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Rosellinia (Xylariaceae) is a large, cosmopolitan genus comprising over 130 species that have been defined based mainly on the morphology of their sexual morphs. The genus comprises both lignicolous and saprotrophic species that are frequently isolated as endophytes from healthy host plants, and important plant pathogens. In order to evaluate the utility of molecular phylogeny and secondary metabolite profiling to achieve a better basis for their classification, a set of strains was selected for a multi-locus phylogeny inferred from a combination of the sequences of the internal transcribed spacer region (ITS), the large subunit (LSU) of the nuclear rDNA, beta-tubulin (TUB2) and the second largest subunit of the RNA polymerase II (RPB2). Concurrently, various strains were surveyed for production of secondary metabolites. Metabolite profiling relied on methods with high performance liquid chromatography with diode array and mass spectrometric detection (HPLC-DAD/MS) as well as preparative isolation of the major components after re-fermentation followed by structure elucidation using nuclear magnetic resonance (NMR) spectroscopy and high resolution mass spectrometry (HR-MS). Two new and nine known isopimarane diterpenoids were identified during our mycochemical studies of two selected Dematophora strains and the metabolites were tested for biological activity. In addition, the nematicidal cyclodepsipeptide PF1022 A was purified and identified from a culture of Rosellinia corticium, which is the first time that this endophyte-derived drug precursor has been identified unambiguously from an ascospore-derived isolate of a Rosellinia species. While the results of this first HPLC profiling were largely inconclusive regarding the utility of secondary metabolites as genus-specific chemotaxonomic markers, the phylogeny clearly showed that species featuring a dematophora-like asexual morph were included in a well-defined clade, for which the genus Dematophora is resurrected. Dematophora now comprises all previously known important plant pathogens in the genus such as D. arcuata, D. bunodes, D. necatrix and D. pepo, while Rosellinia s. str. comprises those species that are known to have a geniculosporium-like or nodulisporium-like asexual morph, or where the asexual morph remains unknown. The extensive morphological studies of L.E. Petrini served as a basis to transfer several further species from Rosellinia to Dematophora, based on the morphology of their asexual morphs. However, most species of Rosellinia and allies still need to be recollected in fresh state, cultured, and studied for their morphology and their phylogenetic affinities before the infrageneric relationships can be clarified.
Collapse
Key Words
- Dematophora
- Dematophora acutispora (Theiss.) C. Lambert, K. Wittstein & M. Stadler
- Dematophora arcuata (Petch) C. Lambert, K. Wittstein & M. Stadler
- Dematophora asperata (Massee ex Wakef.) Lambert, K. Wittstein & M. Stadler
- Dematophora beccariana (Ces.) C. Lambert, K. Wittstein & M, Stadler
- Dematophora boedijnii (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora bothrina (Berk. & Broome) C. Lambert, K. Wittstein & M. Stadler
- Dematophora bunodes (Berk. & Broome) C. Lambert, K. Wittstein & M. Stadler
- Dematophora buxi (Fabre) C. Lambert, K. Wittstein & M. Stadler
- Dematophora compacta (Takemoto) C. Lambert, K. Wittstein & M. Stadler
- Dematophora francisiae (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora freycinetiae (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora gigantea (Ellis & Everh.) C. Lambert, K. Wittstein & M. Stadler
- Dematophora grantii (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora hsiehiae (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora hughesii (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora javaensis (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora macdonaldii (Bres.) C. Lambert, K. Wittstein & M. Stadler
- Dematophora obregonii (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora obtusiostiolata (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora paraguayensis (Starbäck) C. Lambert, K. Wittstein & M. Stadler
- Dematophora pepo (Pat.) C. Lambert, K. Wittstein & M. Stadler
- Dematophora puiggarii (Pat.) C. Lambert, K. Wittstein & M. Stadler
- Dematophora pyramidalis (Lar.N. Vassiljeva) C. Lambert, K. Wittstein & M. Stadler
- Dematophora samuelsii (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Dematophora siggersii (L.E. Petrini) C. Lambert, K. Wittstein & M. Stadler
- Genus resurrection
- Isopimarane diterpenoids
- PF1022A
- Polythetic taxonomy
- Rosellinia
- Xylariaceae
Collapse
Affiliation(s)
- K Wittstein
- Helmholtz-Zentrum für Infektionsforschung GmbH, Department Microbial Drugs, Inhoffenstrasse 7, Braunschweig, 38124, Germany.,German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Braunschweig, 38124, Germany
| | - A Cordsmeier
- Helmholtz-Zentrum für Infektionsforschung GmbH, Department Microbial Drugs, Inhoffenstrasse 7, Braunschweig, 38124, Germany.,University Hospital Erlangen, Institute of Microbiology - Clinical Microbiology, Immunology and Hygiene, Wasserturmstraße 3/5, Erlangen, 91054, Germany
| | - C Lambert
- Helmholtz-Zentrum für Infektionsforschung GmbH, Department Microbial Drugs, Inhoffenstrasse 7, Braunschweig, 38124, Germany.,German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Braunschweig, 38124, Germany
| | - L Wendt
- Helmholtz-Zentrum für Infektionsforschung GmbH, Department Microbial Drugs, Inhoffenstrasse 7, Braunschweig, 38124, Germany.,German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Braunschweig, 38124, Germany
| | - E B Sir
- Instituto de Bioprospección y Fisiología Vegetal-INBIOFIV (CONICET-UNT), San Lorenzo 1469, San Miguel de Tucumán, Tucumán, 4000, Argentina
| | - J Weber
- Helmholtz-Zentrum für Infektionsforschung GmbH, Department Microbial Drugs, Inhoffenstrasse 7, Braunschweig, 38124, Germany.,German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Braunschweig, 38124, Germany
| | - N Wurzler
- Helmholtz-Zentrum für Infektionsforschung GmbH, Department Microbial Drugs, Inhoffenstrasse 7, Braunschweig, 38124, Germany.,German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Braunschweig, 38124, Germany
| | - L E Petrini
- Via al Perato 15c, Breganzona, CH-6932, Switzerland
| | - M Stadler
- Helmholtz-Zentrum für Infektionsforschung GmbH, Department Microbial Drugs, Inhoffenstrasse 7, Braunschweig, 38124, Germany.,German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Braunschweig, 38124, Germany
| |
Collapse
|
44
|
Bézé S, Benoist d'Azy C, Lambert C, Chiambaretta F. [Efficacy of visual rehabilitation of patients with pellucid marginal degeneration fitted with SPOT® scleral contact lenses]. J Fr Ophtalmol 2020; 43:237-242. [PMID: 31955866 DOI: 10.1016/j.jfo.2019.03.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 03/18/2019] [Accepted: 03/20/2019] [Indexed: 10/25/2022]
Abstract
PURPOSE To assess visual improvement in patients with pellucid marginal degeneration (PMD) after fitting with SPOT® scleral contact lenses (Scleral Protection & Ocular Treatment, Laboratoires d'Appareillage Oculaire, Amphion-Les-Bains, France). METHODS We report a case series of 5 patients with PMD and unsatisfactory refractive correction managed at Clermont-Ferrand university hospital from January to December 2018 fitted with customized SPOT scleral lenses. We assessed the best-corrected visual acuity (BVCA) before and after fitting with SPOT, keratometric data and tolerability of the scleral lenses. RESULTS Nine eyes of 5 patients aged 51.8±8.47 years were fitted. The BVCA was significantly improved from 0.51 logMAR (±0.39) to 0.04 logMAR (±0.07) (P<0.001). Sixty-six percent of the patients recovered optimal BVCA. No serious adverse event was reported. The presence of whitish deposits and an inordinate amount of manipulation required were the main disadvantages of the lenses. Nevertheless, all the patients considered them to be comfortable. CONCLUSION Fitting PMD patients who have failed conventional optical devices with SPOT scleral lenses significantly improves BCVA, without serious adverse events, allowing surgery to be deferred even when it appears to be unavoidable.
Collapse
Affiliation(s)
- S Bézé
- Ophthalmology service, centre hospitalier régional universitaire Gabriel-Montpied, place Henri-Dunant, 63000 Clermont-Ferrand, France.
| | - C Benoist d'Azy
- Ophthalmology service, centre hospitalier régional universitaire Gabriel-Montpied, place Henri-Dunant, 63000 Clermont-Ferrand, France
| | - C Lambert
- Délégation à la recherche clinique et informatique, centre hospitalier régional universitaire Gabriel-Montpied, place Henri Dunant, 63000 Clermont-Ferrand, France
| | - F Chiambaretta
- Ophthalmology service, centre hospitalier régional universitaire Gabriel-Montpied, place Henri-Dunant, 63000 Clermont-Ferrand, France
| |
Collapse
|
45
|
Figorilli M, Marques AR, Vidal T, Delaby L, Meloni M, Pereira B, Lambert C, Puligheddu M, Durif F, Fantini ML. Does REM sleep behavior disorder change in the progression of Parkinson's disease? Sleep Med 2020; 68:190-198. [PMID: 32044557 DOI: 10.1016/j.sleep.2019.12.013] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 12/13/2019] [Accepted: 12/20/2019] [Indexed: 11/26/2022]
Abstract
OBJECTIVES/BACKGROUND Rapid eye movement (REM) Sleep Behavior Disorder (RBD) in Parkinson's disease (PD) may be associated with a malignant phenotype. Despite its prognostic value, little is known about the time course of RBD in PD. In this study, we aimed to ascertain whether or not RBD is a stable feature in PD. In this study, we prospectively evaluated clinical and neurophysiological features of RBD, including REM Sleep Without Atonia (RSWA), in PD patients with RBD at baseline and after three years then assessed whether the changes in measures of RSWA parallel the progression of PD. PATIENTS/METHODS In sum, 22 (17M, mean age 64.0 ± 6.9 years) moderate-to-advanced PD patients (mean PD duration at baseline:7.6±4.8 years) with RBD, underwent a video-polysomnography (vPSG) recording and clinical and neuropsychological assessment at baseline and after three years. RESULTS At follow-up, the self-assessed frequency of RBD symptoms increased in six patients, decreased in six and remained stable in 10, while RSWA measures significantly increased in all subjects. At follow-up, patients showed worse H&Y stage (p = 0.02), higher dopaminergic doses (p = 0.05) and they performed significantly worse in phonetic and semantic fluency tests (p = 0.02; p = 0.04). Changes in RSWA correlated significantly with the severity in levodopa-induced dyskinesia (r = 0.61,p = 0.05) and motor fluctuation (r = 0.54,p = 0.03) scores, and with the worsening of executive functions (r = 0.78,p = 0.001) and visuo-spatial perception (r = -0.57,p = 0.04). CONCLUSION Despite the subjective improvement of RBD symptoms in one-fourth of PD patients, all RSWA measures increased significantly at follow-up, and their changes correlated with the clinical evolution of motor and non-motor symptoms. RBD is a long-lasting feature in PD and RSWA is a marker of the disease's progression.
Collapse
Affiliation(s)
- M Figorilli
- EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Sleep Disorder Center, Dept of Public Health & Clinical and Molecular Medicine. University of Cagliari, Italy
| | - A R Marques
- EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Neurology Department, CHU, Clermont-Ferrand, France
| | - T Vidal
- CMRR, CHU, Clermont-Ferrand, France
| | - L Delaby
- CMRR, CHU, Clermont-Ferrand, France
| | - M Meloni
- Sleep Disorder Center, Dept of Public Health & Clinical and Molecular Medicine. University of Cagliari, Italy
| | - B Pereira
- Biostatistics Unit (DRCI), CHU, Clermont-Ferrand, France
| | - C Lambert
- Biostatistics Unit (DRCI), CHU, Clermont-Ferrand, France
| | - M Puligheddu
- Sleep Disorder Center, Dept of Public Health & Clinical and Molecular Medicine. University of Cagliari, Italy
| | - F Durif
- EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Neurology Department, CHU, Clermont-Ferrand, France
| | - M L Fantini
- EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Neurology Department, CHU, Clermont-Ferrand, France.
| |
Collapse
|
46
|
Eschalier R, Massoullie G, Nahli Y, Jean F, Combaret N, Ploux S, Souteyrand G, Chabin X, Bosle R, Lambert C, Chazot E, Bordachar P, Motreff P, Pereira B, Clerfond G. New-Onset Left bundle branch block after TAVI has a deleterious impact on left ventricular systolic function. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Tokhadze N, Chennell P, Bernard L, Lambert C, Pereira B, Mailhot-Jensen B, Sautou V. Impact of alternative materials to plasticized PVC infusion tubings on drug sorption and plasticizer release. Sci Rep 2019; 9:18917. [PMID: 31831771 PMCID: PMC6908714 DOI: 10.1038/s41598-019-55113-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 11/19/2019] [Indexed: 11/09/2022] Open
Abstract
Medical tubings in plasticized polyvinylchloride (PVC) are widely used for the infusion of medications but are known in some cases to cause content-container interactions (drug sorption and plasticizer release). The aim of this study was to assess interactions between drugs and five alternative materials to a reference plasticized PVC intravenous (IV) infusion tubing: three were PVC coextruded with polyethylene (PE), polyurethane (PU) or a thermoplastic elastomer (Styrene-EthyleneButadiene-Styrene (SEBS)) and two were SEBS or thermoplastic olefin (TPO) monolayer tubings. Diazepam and insulin were chosen as respective reference of absorption and adsorption while paracetamol acted as a negative control. The concentration of each drug was quantified with liquid chromatography to evaluate a potential loss after a static contact condition and simulated infusion at 1 mL/h and 10 mL/h dynamic condition by an electric syringe pump. A characterization of each material's surface was performed by Fourier transform infrared spectroscopy in attenuated total reflection mode (ATR-FTIR) and by measurement of surface zeta potential. Plasticizer release was quantified by gas chromatography coupled with mass spectrometry (GC-MS). For all tubings except PVC/PU, no loss of paracetamol was observed in any condition. Diazepam sorption appeared to be less important with PVC/PE, PVC/SEBS, SEBS and TPO tubings than with PVC, but was more important when using PVC/PU tubings. PVC tubings induced the least loss of insulin amongst all the studied materials. Surface analysis by ATR-FTIR highlighted the presence of a plasticizer (that could be attributed to Tris (2-Ethylhexyl) Trimellitate (TOTM)) in the coextruded SEBS layer of PVC/SEBS, which could have influenced drug sorption, probably as a consequence of a migration from the PVC layer. Coextruded PVC/SEBS and PVC/PE presented the lowest zeta potential of all studied materials with respective values of -39 mV and -36 mV and were related to the highest sorption of insulin while PVC/PU with the highest zeta potential (about -9 mV) presented the highest absorption of diazepam. Coextruded layered materials appeared to have a lower plasticizer release than PVC alone. As a conclusion, PVC/PE and thermoplastic elastomers alone or coextruded with PVC could be interesting alternatives to PVC tubings with regards to sorption phenomena and plasticizer release.
Collapse
Affiliation(s)
- N Tokhadze
- Universite Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000, Clermont-Ferrand, France
| | - P Chennell
- Universite Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000, Clermont-Ferrand, France.
| | - L Bernard
- Universite Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000, Clermont-Ferrand, France
| | - C Lambert
- Unité De Biostatistiques (Délégation à La Recherche Clinique Et à l'Innovation), CHU de Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - B Pereira
- Unité De Biostatistiques (Délégation à La Recherche Clinique Et à l'Innovation), CHU de Clermont-Ferrand, 63000, Clermont-Ferrand, France
| | - B Mailhot-Jensen
- Universite Clermont Auvergne, CNRS, SIGMA Clermont, ICCF, F-63000, Clermont-Ferrand, France
| | - V Sautou
- Universite Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000, Clermont-Ferrand, France
| |
Collapse
|
48
|
Bézé S, Benoist D'azy C, Lambert C, Chiambaretta F. Efficacy of visual rehabilitation of patients with pellucid marginal degeneration fitted with SPOT® scleral contact lenses. J Fr Ophtalmol 2019; 43:e1-e5. [PMID: 31836294 DOI: 10.1016/j.jfo.2019.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 10/10/2019] [Accepted: 11/17/2019] [Indexed: 10/25/2022]
Abstract
PURPOSE To assess visual improvement in patients with pellucid marginal degeneration (PMD) after fitting with SPOT® scleral contact lenses (Scleral Protection & Ocular Treatment, Laboratoires d'Appareillage Oculaire, Amphion-Les-Bains, France). METHODS We report a case series of 5 patients with PMD and unsatisfactory refractive correction managed at Clermont-Ferrand university hospital from January to December 2018 fitted with customized SPOT scleral lenses. We assessed the best-corrected visual acuity (BCVA) before and after fitting with SPOT, keratometric data and tolerability of the scleral lenses. RESULTS Nine eyes of 5 patients aged 51.8±8.47 years were fitted. The BCVA was significantly improved from 0.51 logMAR (±0.39) to 0.04 logMAR (±0.07) (P<0.001). Sixty-six percent of the patients recovered optimal BCVA. No serious adverse event was reported. The presence of whitish deposits and an inordinate amount of manipulation required were the main disadvantages of the lenses. Nevertheless, all the patients considered them to be comfortable. CONCLUSION Fitting PMD patients who have failed conventional optical devices with SPOT scleral lenses significantly improves BCVA, without serious adverse events, allowing surgery to be deferred even when it appears to be unavoidable.
Collapse
Affiliation(s)
- S Bézé
- Ophthalmology service, centre hospitalier régional universitaire Gabriel-Montpied, place Henri-Dunant, 63000 Clermont-Ferrand, France.
| | - C Benoist D'azy
- Ophthalmology service, centre hospitalier régional universitaire Gabriel-Montpied, place Henri-Dunant, 63000 Clermont-Ferrand, France
| | - C Lambert
- Délégation à la recherche clinique et informatique, centre hospitalier régional universitaire Gabriel-Montpied, place Henri-Dunant, 63000 Clermont-Ferrand, France
| | - F Chiambaretta
- Ophthalmology service, centre hospitalier régional universitaire Gabriel-Montpied, place Henri-Dunant, 63000 Clermont-Ferrand, France
| |
Collapse
|
49
|
Figorilli M, Marques A, Vidal T, Delaby L, Meloni M, Pereira B, Lambert C, Puligheddu M, Durif F, Fantini M. REM sleep behavior disorder changes in the progression of Parkinson's disease: a longitudinal study. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Lambert C, Borderie D, Dubuc JE, Rannou F, Henrotin Y. Type II collagen peptide Coll2-1 is an actor of synovitis. Osteoarthritis Cartilage 2019; 27:1680-1691. [PMID: 31325494 DOI: 10.1016/j.joca.2019.07.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 06/18/2019] [Accepted: 07/01/2019] [Indexed: 02/02/2023]
Abstract
OBJECTIVE We evaluated the ability of Coll2-1, a type II collagen peptide, to activate pro-inflammatory pathways in synovial cells and to induce arthritis in Lewis rats. METHOD Human synoviocytes and chondrocytes from knee OA patients were cultured for 24 h with/without Coll2-1 and/or purified immunoglobulin G (AS0619) binding specifically this peptide, and/or CLI-095, a TLR-4 signaling inhibitor and/or apocynin and diphenyleneiodonium, Reactive oxygen species (ROS) production inhibitors. The Interleukin (IL)-8 and Vascular Endothelium Growth Factor (VEGF) expression, the IL-8 production, the IκB-α and p65 phosphorylation and ROS were evaluated. Coll2-1 peptide, bovine type II collagen (CIA), streptococcal cell wall (SCW) or saline solution were injected into Lewis rats. The Coll2-1 peptide was injected subcutaneously (SC; 20-200μg/100μl/animal) or intra-articularly (IA; 0.5-5μg/50μl/animal) and compared to CIA injected in SC (200μg/100μl/animal) and SCW in IA (5μg/50μl/animal). The animals were injected on day 0 and monitored for 28 days. Histological lesions assessment was performed using an arthritis score. RESULTS Coll2-1 peptide significantly increased IL-8 gene expression and production by synoviocytes. AS0619 and CLI-095 significantly decreased IL-8 expression. Coll2-1 induced p65 and IκBα phosphorylation and oxidative stress inhibitors decreased it. In human chondrocytes culture, Coll2-1 significantly increased MMP-3 and VEGF gene expression. In Lewis rats, CIA, SCW or Coll2-1 injection triggered arthritis. Like CIA or SCW, Coll2-1 induced synovitis, loss of cartilage proteoglycans, cartilage structure lesion and subchondral bone remodeling. CONCLUSIONS Coll2-1 activates synoviocytes to produce IL-8 and induces arthritis in rat. These findings suggest that neutralizing Coll2-1 could be a therapeutic approach of arthritis.
Collapse
Affiliation(s)
- C Lambert
- Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, Institute of Pathology, CHU Sart-Tilman, 4000, Liège, Belgium.
| | - D Borderie
- INSERM UMR 1124, Laboratory of Pharmacology, Toxicology and Cell Signaling, University Paris-Descartes, Paris, France; Department of Automated Biological Diagnostic, Cochin Hospital, APHP, University Paris Descartes, Paris, France.
| | - J-E Dubuc
- Orthopaedic Department, University Hospital Saint-Luc, Brussels, Belgium.
| | - F Rannou
- INSERM UMR 1124, Laboratory of Pharmacology, Toxicology and Cell Signaling, University Paris-Descartes, Paris, France; Department of Physical Medicine and Rehabilitation, Rheumatology Institute, Cochin Hospital, APHP, University Paris Descartes, Paris, France.
| | - Y Henrotin
- Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, Institute of Pathology, CHU Sart-Tilman, 4000, Liège, Belgium; Department of Physical Therapy and Rehabilitation, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Belgium; Artialis S.A., Tour GIGA, Level 3, CHU Sart-Tilman, 4000, Liège, Belgium.
| |
Collapse
|